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ABSTRACT 
Introduction and aim: Spinal cord stimulation (SCS) has been used for treatment of 
otherwise therapy-resistant chronic neuropathic pain for about four decades. However, 30-40 % 
of the patients do not benefit from SCS, despite careful case selection and technical advances. 
In search of ways to improve the outcome mechanisms underlying the pain relieving effect of 
SCS have been extensively explored. Experimental findings suggest a possibility to enhance the 
effect of SCS by concomitant intrathecal (i.t.) administration of pharmaceuticals, such as 
baclofen, clonidine and adenosine.  
Animal research has indicated that hypersensitivity to colonic dilatation can be attenuated 
by SCS. This finding, as well as related clinical observations, forms a basis for the possibility of 
treating irritable bowel syndrome (IBS) with SCS.  
Implantation of an SCS system with a plate electrode requires extensive surgery. This can 
be painful and cumbersome for the patient, since finding an optimal electrode position demands 
patient cooperation with reporting of stimulation evoked sensations.  
Aims of the thesis were to study: 1) if co-administration of baclofen (Study I and III), 
clonidine (Study III) or adenosine (Study I) can enhance the effect of SCS, 2) if long-term i.t. 
administration of a drug will continue to support the effect of SCS over time (Study II), 3) if 
implantation of plate electrodes can be performed in spinal anesthesia, retaining the possibility 
for the patient to feel and report stimulation evoked paresthesias and 4) if SCS can be used as a 
treatment option for IBS, otherwise resistant to therapy. 
Methods: In Study I, 43 patients with neuropathic pain either experiencing diminished 
effect of previously efficacious SCS or with insufficient initial effect of SCS were recruited for 
trials of bolus i.t. injections of baclofen. Patients responding to the addition of baclofen were 
offered continued administration either i.t., via an implanted pump, or orally. Seven patients 
were also tested with i.t. adenosine. In Study II, the patients who continued with i.t. baclofen 
via a pump were assessed for long-term results. In Study III, 10 neuropathic pain patients with 
insufficient effect of SCS were recruited for a randomized double-blind trial, with i.t. injections 
of baclofen, clonidine and placebo. In Study IV, results from 20 implantations of plate 
electrodes in spinal anesthesia are reported. In Study V, 10 patients with IBS participated in a 
study of SCS, comparing randomly assigned periods of active stimulation versus a period 
without stimulation. 
Results: In Study I, 20 patients responded to i.t. baclofen, with or without SCS. Three 
patients tested oral baclofen as an adjunct to SCS, but terminated treatment due to side effects. 
Eleven patients had pumps implanted, two of which were explanted during the trial period. Two 
patients opted for i.t. adenosine delivery via a pump, but discontinued due to side effects. In 
Study II, it was confirmed that all 9 patients with remaining working pumps continued to 
benefit from the therapy, albeit with a dose increase. In Study III, 5 patients responded to either 
baclofen or clonidine and 4 received pumps for i.t. delivery (2 baclofen, 2 clonidine).  In Study 
IV, it was demonstrated that in all 20 implantations it was possible to perform successful intra-
operative testing in spinal anesthesia. In Study V, 6 out of 9 patients responded beneficially to 
SCS as a treatment for IBS (1 patient left the study). 
Conclusions: I.t. medication with baclofen or clonidine can enhance the effect of SCS. 
This enhancement remains over a long-term follow up. Implantations of plate electrodes can be 
performed with intra-operative testing in spinal anesthesia. SCS may alleviate pain in IBS, but 
studies in larger patient materials are needed to investigate effects on other IBS symptoms. 
Key words: spinal cord stimulation, neuropathic pain, baclofen, clonidine, adenosine, 
intrathecal medication, IBS 
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1 INTRODUCTION 
Spinal cord stimulation (SCS) has been in clinical use for about four 
decades. It has evolved as a useful, minimally invasive, cost-efficient and 
reversible therapy for certain forms of chronic pain, when pharmacological 
treatment has failed. SCS requires operative implantation of a stimulating 
electrode connected to a subcutaneous pulse generator. The individual patient 
can turn the stimulation on and off at will and adjust the stimulation intensity. 
Stimulation is accompanied by a tingling sensation, paresthesia. 
For some pain indications the evidence for the SCS efficacy is satisfactory. 
The usage is wide-spread with, at present, about 30,000 implants performed 
globally each year199. 
Many patients with severe pain, however, do not benefit from SCS, despite 
adequate indication and implant technique. It is important that we advance the 
knowledge of the mechanisms of action of SCS to enable the development of 
methods for improving the outcome. 
1.1 PAIN AND PAIN ASSESSMENT 
Pain is the result of a process of utmost importance for survival, namely the 
swift recognition and prompt reaction to potentially harmful influences on the 
body. The process itself is called nociception. Pain and nociception are, 
however, not identical entities. Nociception is a physiological process whilst 
pain is a phenomenon experienced by the sufferer. Pain can occur without 
nociception and nociception does not always result in pain, as can be the case 
when a patient uses an analgetic. Pain is described by the International 
Association for the Study of Pain (IASP) as: “an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage”140. 
Pain is the most common symptom among health-care seekers. In a 
Canadian survey ⅔ of the patients presenting at the emergency department had 
pain146 and in a Finnish primary health care study pain was recognized as the 
reason for 40 % of the visits238. 
1.1.1 Classification of pain 
The notion of pain comprises different subtypes. The most obvious 
subdivision of pain is based on time: acute and chronic pain. There is no 
universally accepted definition of these terms, but a classification of pain lasting 
less than 3 months “acute” and pain lasting more than three months “chronic” 
has been proposed166, as well as several other definitions.  
Another subdivision of pain relates to the underlying mechanism believed to 
constitute the background for each form of pain. The kind of pain that arises 
from stimulation of nociceptors, the receptors specifically activated by noxious 
stimuli (i.e. an actually or potentially tissue damaging event), is called 
nociceptive pain. This type of pain is defined by IASP simply as “pain arising 
from activation of nociceptors”202. It is, however, clear that not all pain can be 
attributed to nociception, as many instances of pain do not have a demonstrable 
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nociceptive background. An illustrative example is phantom limb pain, which is 
independent of nociceptor activation. This is a type of non-nociceptive pain that 
is denoted as neuropathic. IASP has defined this as “pain initiated or caused by 
a primary lesion or dysfunction in the nervous system”. Recently a somewhat 
different and more restrictive definition has been proposed: “pain arising as a 
direct consequence of a lesion or disease affecting the somatosensory system”341. 
Even though this definition is not the one used in the publications of this thesis it 
would not have had any impact on patient recruitment for the studies presented, 
i.e. none of the patients with neuropathic pain involved in the studies would have 
been reclassified as not having neuropathic pain if the new definition had been 
applied.  
Nociceptive and neuropathic pain are not necessarily mutually exclusive and 
may coexist. Nevertheless, it is of utmost importance to adequately analyze pain 
and to identify its nature and different components, because treatment options 
differ depending on the type of pain.  
Both the terms neuropathic and nociceptive are generalized terms 
incorporating many subclassifications. Nociceptive pain may be subdivided 
depending on the character of the noxious stimulus, such as ischemic or 
inflammatory pain. Neuropathic pain may be of central or peripheral origin, and 
several other subdivisions exist, many of which have separate definitions in the 
IASP taxonomy140. Instead of neuropathic the term neurogenic is sometimes 
used.  
Other pain classifications that have been in use, but less frequently during 
the past decade, are psychogenic and idiopathic pain. Psychogenic pain would 
be used for pain associated with psychological or psychiatric factors, e.g. 
defined in “Bonica’s management of pain” as “report of pain attributable 
primarily to psychological factors usually in the absence of any objective 
physical pathology that could account for pain”344. The entity of psychogenic 
pain has been much questioned and distinguishing it from other forms of pain 
can be difficult336,337. Idiopathic as a medical term is used to describe an entity of 
obscure or unknown origin or spontaneous appearance. Idiopathic pain in that 
sense can be used as a term for pain of unknown origin. The term, however, has 
been much used for specific syndromes frequently accompanied with pain, 
where the pain component of the syndrome is less readily fully explained, such 
as temporomandibular joint disorders, chronic headaches, whiplash-associated 
disorders etc.59 Neither psychogenic pain nor idiopathic pain is presently 
included in the IASP pain taxonomy. 
Other subdivisions of pain relate to the part of the body where the pain 
occurs, such as headache, abdominal pain, elbow pain, etc. Pain can also be 
classified according to its severity or from underlying pathology, such as 
rheumatological pain and cancer pain. 
An important step in the field of pain classification is the ongoing process of 
developing a classification based on mechanisms. In an editorial in the journal 
“Pain” an expert group has proposed foundations for such a classification, with 
the hope that a mechanism-based classification will lead to better medical 
treatment of pain tailored to mechanisms361. They list three major categories: 
transient pain - pain as a response to a passing noxious stimulus that does not 
produce a lasting impact, such as a pin prick, tissue injury pain and nervous 
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system injury pain, with subclassifications based on underlying mechanisms. A 
non-mechanism based classification may lead to misinterpretation of symptoms 
and signs, for example allodynia can occur not only from nervous system injury 
but may appear with tissue injury as well361. 
1.1.2 Assessment of pain 
Since pain is an exclusively subjective entity its intensity and character can 
only be described by the sufferer. This is not easily performed (nor easily 
standardized) and Virginia Woolf described this in an often cited passage from 
her 1930 book On being ill:”let a sufferer try to describe a pain in his head to a 
doctor, and language runs at once dry". 
In 1947 Hardy, Wolff and Goodell presented experiments on the perception 
of heat induced pain (with themselves as subjects)110. They claimed that in 
between the slightest stimulus perceived as pain and the ceiling intensity of 
stimulation (above which an increase in stimulation intensity did not lead to a 
more intense perception of pain) no more than 21 steps could be discriminated. 
They proposed the unit “dol”, corresponding to two such steps, as a 
measurement for pain. Furthermore, they devised an apparatus, the 
“dolorimeter”, which could be used for the purpose of producing a graded 
painful stimulus to a patient in pain so that he or she could report if the pain 
induced by the dolorimeter corresponded to the original pain (yielding a 
specified number of “dols”). The method was tried in some scientific studies but 
was soon abandoned118. Patients were hesitant to experience the pain twice and 
sometimes even hostile to the experimenters9. 
 Another early attempt to standardize reports on pain intensity was “The 
pain chart”, described by Keele in Lancet 1948157. The chart was set up with 
grades (0-4) corresponding to different pain intensities, each grade described by 
a defined word (“nil”, “slight", " moderate", " severe" and " agonising"). In the 
classic human experiments on pain-producing substances of Keele and 
Armstrong the subjects moved a pointer along a scale marked with these 
numbers (0-4) during the experiments, yielding a continuous analogue recording 
of perceived pain intensity156.  
In 1965 a case of phantom limb pain was presented, where the patient had 
been instructed to repeatedly assess his pain by making a pencil mark on a 10 
cm line with the label “No pain at all” on the right side and “As painful as it 
could possibly be” on the left side266. By simply measuring the distance from the 
right end of the line to the mark a “pain score” was acquired. The notion of 
using graphic representations for assessments was adopted from the social 
sciences and psychology, where it had been in use since the 1920ies88,120, and the 
idea of putting a mark on a 10 cm line between a verbal description of extremes 
and in millimeters measure the distance to produce a score was presented from 
the fields of psychology and psychiatry39. This method of assessing pain was 
soon adopted by many researchers and during the subsequent decade the phrase 
“Visual Analogue Scale” (abbreviated VAS) was adopted as a term for this 
graphic pain scale2,139,147,360. The VAS scale has subsequently proven to be one 
of the most common ways of reporting pain intensity, either transferring the 
scale to numeric values by measuring in mm (0-100) or in cm (0-10). 
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Other common scales for pain assessment are the Numeric Rating Scale 
(NRS) and the Verbal Rating Scale (VRS). VRS constitutes of a set number of 
verbal descriptors, each representing an increasingly intense pain and each 
corresponding to a number, e.g. 0-4 as in “The pain chart” mentioned 
previously. NRS is a scale, as the VAS, where only the extremes are anchored in 
words: 0 set to mean “no pain” and the highest number, be it 5, 10 or 100, 
corresponding to e.g. “worst pain imaginable”. NRS and VRS are frequently 
accompanied by a number indicating the total number of choices, e.g. NRS-11 
(0-10), NRS-101 (0-100) or VRS-4 (such as “The pain chart”). In Figure 1 
examples of VAS, NRS and VRS are given.  
Numerous comparisons of these pain assessment scales have been 
published. It is evident that verbal rating cannot in an exact manner be 
transformed into numerical or visual rating or the opposite207, but nonetheless 
several studies indicate a fair correspondence between VAS and NRS78,269. In a 
recent comprehensive literature review of comparisons of VAS, VRS and NRS 
the authors conclude that:” the results show that NRS-11, VRS-7, or VAS all 
work quite well. … the most important choice is not the type of scale per se, but 
the conditions related to its use …”125. It should be noted that even though VAS, 
NRS and VRS may end up in figures that can be identical the methods are 
different. If a patient is asked to give a number to describe the intensity of pain 
the kind of scale used should be referred to as NRS and not VAS despite the fact 
that processing the data will yield similar figures. It is, however, not uncommon 
that inappropriate labeling of a scale is performed (and that in fact is also the 
case in some of the studies presented in this thesis). 
A number of publications have been presented concerning changes in 
assessed pain, in order to determine the magnitude of change that is of 
importance for a patient. In absolute measures a change of 13 mm on the VAS 
 
□ No pain 
□ Mild pain 
□ Moderate pain 
□ Severe pain 
□ Unbearable pain 
VRS-5 
Please indicate your present pain 
PGIC-5 
□ Much better 
□ Slightly better 
□ No change 
□ Slightly worse 
□ Much worse 
Please indicate how your pain has 
changed since you entered the study 
Worst pain 
imaginable 
0 1 2 3 4 5 6 7 8 9 10
VAS Please mark your present pain 
NRS-11 Please indicate your present pain 
No pain Worst pain 
imaginable 
No pain 
Figure 1: Examples of commonly used pain scales 
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scale20,90,338 or of one unit in the NRS-11 scale289 has been proposed as a 
minimum requirement for an apparent true change. For a change of clinical 
significance, however, a relative change of 30 %76,144,289 or even 50 %84 has been 
advocated, based on clinical studies. There are also scales for assessing change 
per se and during the past decade many publications on pain have used Patient’s 
Global Impression of Change (PGIC) as a measurement of alteration of pain 
intensity76,289. The PGIC scale consists of verbal statements, frequently 5 or 7, 
where the patient is instructed to choose one to describe the change between to 
specified points in time (such as e.g. “since the start of the study until now”). 
The statements can be e.g. (for PGIC-7) ‘‘very much better’’, ‘‘much better’’, 
‘‘slightly better’’, ‘‘no change’’, ‘‘slightly worse’’, ‘‘much worse’’ or ‘‘very 
much worse’’. One draw-back of this kind of scale can be that the patient may 
have difficulties in recalling a previous intensity of pain. 
The aforementioned scales are all unidimensional, in that they solely 
measure the intensity of pain. There are also pain rating instruments taking other 
modalities into account. The McGill Pain Questionnaire, developed by Melzack 
at McGill University, is probably the one most commonly used222. The 
questionnaire allows for the patient to select a number of verbal descriptors 
related to pain (such as “dull”, ”vicious”, ”unbearable” – 102 words in total, 
subdivided in three classes and sixteen subclasses) apart from rating the pain 
intensity. 
The VAS and NRS yield numbers and are by some viewed as ratio scales. 
Some studies concerning the distribution of VAS and NRS ratings support the 
claim that the scales are linear115,235,236, but this has been questioned265. These 
considerations are of importance for the choice of statistical analysis methods 
when applied for pain scales. Non-parametric statistical methods are presently 
generally recommended for such  scales216,327, even though there are many 
publications where parametric statistics have been used (e.g.215). 
1.2 SPINAL CORD STIMULATION – BACKGROUND 
In the first issue of the journal “Pain” Kane and Taub give an interesting and 
commendable account of “A history of local electrical analgesia”148. Electrical 
stimulation has been used for the treatment of pain for thousands of years148. 
Natural sources of electricity seem to have been used, such as the torpedo ray 
(electric ray) or the Nile catfish. Even etymologically there is evidence of this 
since the greek word for torpedo ray is “narke”, meaning “numbing”, a word the 
root of which is used in narcosis148. The oldest written account of the use of 
electricity for pain dates back to the descriptions of Scribonius Largus, from 
around 46 A.D., on how the use of a live torpedo fish can ease headache or the 
pain of gout 148. Numerous accounts of the continued use of natural sources of 
electricity exist and since the 18th century apparatuses producing electricity came 
into use for medical purposes. There are many accounts of the use of 
electroanalgesia during the 19th century, even for anesthetic purposes during 
tooth extractions and surgical procedures, including amputations148. In the early 
20th century a device for electrical stimulation, the “Electreat”, was marketed95. 
It had some resemblances to a modern TENS apparatus and was provided with a 
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small sign reading “Electreat relieves pain”. It has been estimated that about 
300 000 of these devices were sold301. 
The earliest attempts to treat pain with electrical stimulation by invasive 
techniques were performed with intracranial electrodes. During the late 50ies 
and early 60ies stimulation of the septal area was tried in a few patients99,121 as 
well as stimulation in the thalamus217. Thus Mazars used stimulation in the 
sensory thalamus to treat severe pain syndromes even before the advent of the 
gate theory, and this application was based on a considerably older theory 
launched by Head and Thompson199. 
In 1965 Melzack and Wall presented a novel theory on the processing of 
pain, the “gate control theory of pain”, stipulating that pain, among other factors, 
is influenced by “the relative balance of activity in large versus small fibers”223. 
They suggested a new perspective to the understanding of pain transmission 
unifying the two prevailing, but mutually opposing, theories of pain transmission 
that had been debated during the early part of the 20th century158,223. One of them 
was called the specificity theory, originally proposed by von Frey in 1894, 
postulating that pain constitutes a modality all of its own with pain receptors and 
pain transmitting peripheral and central connections, in essence a direct line 
from pain impulse to the brain. The other theory was called the pattern or 
summation theory, suggested by Goldscheider, also in 1894, proposing that pain 
perception is the result of summation of impulses from receptors not by 
themselves primarily directed to react to pain. Neither of these theories could 
fully explain all features of how pain is experienced and during the 20th century 
modifications of these theories were brought forth158. The “gate control theory”, 
though much criticized199, has however, serve as an important foundation that 
has generated a wealth of pain research. In an editorial from 2001 Dickenson 
summarizes the impact of this theory by stating that the “Gate control theory of 
pain stands the test of time”60. 
The “gate control theory” spurred the interest in electrical stimulation for 
pain relief. In January 1967 Wall and Sweet presented eight patients treated for 
pain with different ways of stimulation of peripheral nerves or nerve roots, either 
with implanted electrodes or electrodes on the skin surface347. Stimulation was 
performed with square-wave pulses at 100 Hz and a pulse width of 0.1 msec. 
The patients reported a tingling sensation and temporary abolition or reduction 
of pain. Later the same year Shealy et al proposed that a logical site for 
stimulation would be the spinal dorsal columns. They presented the results with 
50 Hz electrical stimulation of the dorsal columns of the cervical cord in cats 
and later in 1967 the first use of such stimulation in a human subject302,303. The 
method evolved quickly and already in 1968 the first commercially available 
equipment for spinal cord stimulation was introduced96. During the first years 
transcutaneous electrical stimulation (TENS) was used for screening patients 
suitable for implantation of spinal cord stimulation (at that time referred to as 
dorsal column stimulation), but soon evolved into a successful pain treatment 
modality by itself205. It has been reported that Shealy initially used the Electreat 
for the purpose of screening patients for SCS, but soon commissioned a more 
versatile and reliable contemporary stimulator95,300,301. 
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1.3 SPINAL CORD STIMULATION – INDICATIONS 
During the first decades of SCS the method was applied to a number of pain 
conditions as well as other pathologies, such as spasticity. Over time it became 
evident that not all types of pain responded to SCS and some forms of pain 
related to injury or malfunction of the nervous system – neuropathic pain - 
evolved as the main indications96. Already in one of the earliest surveys of SCS, 
by Nashold and Friedman, it was noted that pain at the site of the surgical wound 
for SCS implantation was not ameliorated even though the effect was excellent 
for the pain targeted for treatment240. One patient was reported to suffer an 
intercurrent bone fracture, the pain of which was not relieved by SCS241. 
Observations of autonomic changes in patients treated with SCS lead Cook 
and coworkers to successfully try SCS for vascular disease of the extremities47. 
The same year Dooley and Kasprak, based on the fact that patients frequently 
reported a feeling of warmth accompanying SCS, examined the effect of SCS on 
the peripheral vasculature. They reported that SCS induced arterial dilatation and 
soon tried it for patients with extremity vascular disease64,65. The observation 
that SCS could be an effective treatment of peripheral vascular disease by 
improving circulation in the limbs5,27,38,136 spurred the interest in applying the 
method to other conditions of ischemia. After initial reports of beneficial effect 
on angina pectoris using TENS213, SCS was shown to be effective for the 
treatment of angina pectoris as well234. When used for treatment of ischemic 
conditions it is likely that the effect of SCS is not primarily a direct pain 
reducing effect, but rather produces pain relief secondary to reduction of tissue 
ischemia produced by the stimulation194,225. 
Clinical studies of SCS have been hampered by the difficulty to blind the 
stimulation to the patient, because of stimulation-induced paresthesias. The fact 
that paresthesias are evoked during effective SCS is not only based on 
experience, but is also a natural result of orthodromic activation of dorsal 
column fibers, in accordance with the gate control theory. The necessity for 
paresthesias covering the painful area for a benificial effect was noted early in 
the evolution of SCS240. In a study on SCS effects on sensory modalities by 
Lindblom and Meyerson in 1975 it was noted that a few patients reported some 
pain reduction with stimulation intensities below the threshold for paresthesias, 
but the pain reduction was less than that obtained with  paresthetic 
stimulation193. Cases with subthreshold SCS but still with marked increases of 
cutaneous blood flow, as demonstrated by thermography, were reported by 
Linderoth in 1995194, and in a recent case study on treatment of Raynaud’s 
phenomenon subthreshold stimulation appeared to have some effect17. 
Subthreshold stimulation has also been tested in two clinical trials of SCS for 
angina. One study showed equal effects of SCS on functional status and angina 
symptoms by paresthetic stimulation and  a stimulation of 85 % of the intensity 
yielding paresthesias, but there was no effect of sham stimulation66. In another 
study, the paresthetic stimulation group had a significantly better outcome than 
both the sham stimulation group and the subliminal stimulation group185. In both 
these studies it was thus possible to apply a blinded stimulation design. On the 
other hand, it is in all cases necessary to ascertain the proper placement of the 
stimulating electrode as well as to determine the perception threshold with at 
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least a short stimulation session. Recently, a different stimulation paradigm has 
been presented in a small trial with “burst stimulation (40-Hz bursts with 5 
spikes at 500 Hz per burst)”, which produced good pain relief without any 
subjective sensations55.  
Numerous studies have reported on the value of SCS for a number of 
indications and during the past decades some prospective randomized, but non-
blinded, controlled trials have been presented. The effectiveness of SCS has 
been demonstrated for pain associated with lumbosacral rhizopathy (often 
referred to as failed back surgery syndrome, “FBSS”)182,211,246, CRPS (type 1)160, 
limb ischemia145,170 and angina pectoris54,66,214,220.  
1.3.1 Present established indications 
1.3.1.1 Lumbosacral radicular pain (FBSS) 
In a study, presented in 2005 by North et al., 50 patients with recurring or 
persistent radicular pain after lumbosacral spinal surgery were randomized either 
to reoperation or SCS246. Eligible patients had a history of one or several 
previous surgical spinal interventions and suffered from radicular pain exceeding 
or equal to their low back pain as well as radiological findings of nerve root 
compression.  Patients were followed for three years and were allowed to cross-
over to the other treatment arm if they considered the effect unsatisfactory. 
Patients randomized to SCS were at first subject to a trial stimulation, with 
permanent implantation provided that at least 50 % pain reduction was achieved. 
At three year follow-up, the SCS group had a significantly higher rate of 
participants achieving a pain reduction exceeding 50 % than that with 
reoperation (47 % and 12 % respectively). The opioid usage was significantly 
lower in the SCS group than in the reoperation group. Fifty-four % of the 
patients in the reoperation group chose to cross-over to reoperation whereas only 
21% of the patients randomized to SCS opted for a reoperation. 
In another study, the PROCESS study (Prospective Randomised Controlled 
Multicentre Trial of the Effectiveness of Spinal Cord Stimulation), 100 patients 
with persistent radicular pain after lumbar disc hernia surgery with successful 
anatomical result were randomized either to conventional medical management 
(CMM) or CMM and SCS. Patients were allowed to cross-over between 
treatments after 6 months. In this study as well, SCS patients started with a trial 
stimulation and were permanently implanted only if they experienced at least 50 
% reduction of the leg pain. Results were reported after one year182, with the 
proportion of patients receiving ≥ 50 % pain relief at 6 month as the primary 
outcome, and again after two years follow-up181. 10 % of the SCS patients chose 
to cross over to CMM and 73 % of the CMM patients demanded to cross over to 
SCS. At 6 month follow-up (i.e. before any cross-over took place) 48 % of the 
SCS patients reported the primary outcome of at least 50 % pain reduction but 
only 9 % of the control group attained that outcome. At the two years follow-up 
the effects of SCS were sustained with a statistically significant difference 
between treatments both in a modified intention-to-treat analysis as well as in a 
final treatment analysis. 
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1.3.1.2 Complex Regional Pain Syndrome (CRPS) 
The effects of SCS on CRPS (Complex Regional Pain Syndrome) have been 
explored in a Dutch study presented as a two years follow-up160 supplemented 
by a final five-year evaluation161. The term CRPS (Table 1) was introduced by 
IASP as an umbrella diagnosis containing conditions previously referred to as: 
reflex sympathetic dystrophy, algodystrophy, Sudeck’s dystrophy, causalgia, 
etc.. In the Dutch study 54 CRPS-1 patients (no patients with CRPS-2 were part 
of this study) were recruited and randomized in a 2:1 fashion to either SCS and 
physiotherapy (PT) or physiotherapy alone. At two years follow-up the reported 
pain intensity was significantly lower in the SCS group than in the PT group. 
However, at five years there was no longer any statistically detectable difference 
between the treatments (p=0.06), in an intention-to-treat analysis. It is worth 
noting that there had been cross-over between groups, with 22 % of the patients 
in the PT group crossing over to SCS and in total 9 % of patients lost to follow-
up. Even at 5 years most SCS patients wanted to continue treatment and found it 
useful. 
1.3.1.3 Limb ischemia 
A number of prospective randomized studies have addressed the effect of 
SCS on limb ischemia. A meta-analysis of these studies can be retrieved from 
the Cochrane Collaboration database345. Six studies comprising almost 450 
patients having chronic critical limb ischemia (CLI), deemed not treatable with 
arterial reconstruction, were evaluated. Patients had resting pain due to ischemia 
or ulcerations smaller than 3 cm in diameter or both and were at risk for 
amputation. For all studies the primary end-point was the limb-salvage rate at 
twelve months (amputation of a foot or higher was considered as non-limb 
salvage). The meta-analysis showed no significant difference between treatment 
groups concerning ulcer healing, but a pooled analysis disclosed a significantly 
higher limb-salvage rate for SCS-treatment as compared to conventional medical 
management. Pain measurements could not be pooled, but in several studies 
patients with SCS-treatment appeared to show significantly better pain 
scores145,319 and less analgesic medication than in the control group318. However, 
a highly significant pain reduction occurred after amputation in patients for 
Diagnostic criteria  for CRPS-1224 
1) presence of an initiating noxious event or 
cause of immobilization  
2) continuing pain, allodynia, or hyperalgesia 
with which the pain is disproportionate to the 
inciting event 
3) evidence at some time of edema, changes 
in skin blood flow, or abnormal sudomotor 
activity in the region of pain 
4) absence of conditions that would otherwise 
account for the degree of pain and dysfunction 
Diagnostic criteria  for CRPS-2 
For CRPS-2 there must be a, partial, nerve 
injury as well as the criteria for CRPS-1 Table 1: Diagnostic criteria for CRPS 
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whom that was inevitable, and pain relief was better for amputated patients than 
for non-amputated patients regardless of treatment318. In a more recently 
published non-randomized study, the long-term effect of SCS for CLI has been 
reported beyond the 12 months scope of the randomized trials. Eightyseven CLI 
patients were permanently implanted with SCS after an initial trial period with 
requirements of both substantial pain reduction and an increase of tcpO2 
(transcutaneous oxygen partial pressure) in the foot. At an average of 48 months 
the beneficial effects of SCS remained and after the second year major 
amputations became infrequent93. 
1.3.1.4 Angina pectoris 
SCS treatment for angina pectoris has been used since 1987/1988212,234 and 
several randomized control studies have been performed. A concise review of 
these studies was presented in 200828, and there is a recent additional 
randomized control trial from 2010185. The evidence that SCS can improve 
quality of life, reduce number of angina attack and increase capacity on treadmill 
was classified as being on a high level. In the largest of the included studies with 
104 patients, the Swedish ESBY-study (Electrical Stimulation versus Coronary 
Artery Bypass Surgery in Severe Angina Pectoris), SCS was compared to 
bypass surgery214. This study showed equal effects on angina symptoms for both 
study groups and a lower mortality in the SCS group.  
1.3.1.5 Abdominal pain 
Already in a publication from 1975 SCS treatment of a gastrointestinal 
ailment is described21. In a study of evoked potentials during SCS the 10 
participating patients are presented in a table and one of them was treated for 
chronic pancreatitis with a “fair” result 21. In 1981 and 1982 an Italian group 
reported on SCS influence on colonic motility. Two patients, one with bifid 
spine and one with MS, had SCS applied at the T8/9 level for their neurological 
disorder, and they reported having a beneficial effect of SCS on their severe 
constipation as well263,264. Later on additional reports on gastrointestinal 
functions of SCS, both beneficial effects and unintended side effects, have 
appeared. Several publications cover treatment of different types of abdominal 
pain (such as chronic pancreatitis, post-surgical intra-abdominal adhesions and 
other forms of post-surgical visceral pain149), where at present over 70 patients 
have been treated successfully, in general after rigorous screening and testing149-
152,163. Additionally two cases of successful treatment of abdominal angina and 
mesenteric ischemia with SCS have been reported31,34. It might be that in these 
two cases the beneficial effects are the result of the same mechanisms that are 
responsible for the increased blood flow/diminished ischemia produced by SCS 
in other ischemic conditions. Some reports also include information about 
gastrointestinal side effects of SCS, also in situations where the electrodes were 
implanted at other locations than the mid-thoracic level where abdominal effects 
could be expected183,334. For example one patient who was successfully treated 
with cervical SCS for CRPS in the arm chose to have the system removed 
because the stimulation repeatedly evoked relapses of, pre-existing but until then 
mild, symptoms of ulcerative colitis159. 
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In the literature only four case reports on SCS applied for irritable bowel 
syndrome (IBS) are available. The first is from 2001 and SCS was without 
effect209. In 2004, on the basis of previously published animal studies102, Krames 
and Moussad reported on a single patient with highly successful SCS treatment 
for IBS173. Finally, in 2012 an additional two case reports with beneficial effects 
of SCS for IBS have been published253,272. 
1.3.1.6 Other forms of pain 
Pain after peripheral nerve injury is an important indication for SCS. Even 
though no RCTs have been performed it is seen as an indication with a high 
likelihood of success155,187,305. 
SCS is also used for a number of other forms of neuropathic pain. This 
includes phantom limb pain230, post-herpetic neuralgia111,221, diabetic 
polyneuropathic pain267 and pain after partial injury to nervous plexus26. No 
RCTs have been performed for these indications, but many non-randomized 
retrospective, as well as some prospective, case series, demonstrating varying 
success have been presented. 
For some other ischemic conditions such as Reynaud’s phenomenon17,285 
and frostbite4 SCS has appeared to be effective in non-randomized, mainly 
retrospective, studies. 
1.3.2  Exploratory and experimental use of SCS 
In the early years of SCS the technique was also used for a number of other 
indications. Especially it was used for spasticity, e.g. in conjunction with 
MS43,141 and spinal cord injury281,282, torticollis97,349 and bladder dysfunction46,169. 
A publication exists were it was tested, with short term success, for amyotrophic 
lateral sclerosis45. SCS has also been tried, with some success, for cerebral 
vasospasm in conjunction with subarachnoid hemorrhage331. There are also a 
few reports were SCS has been tested as an adjuvant to spinal cord injury 
rehabilitation with improvement of motor function13,30,113,124,169. Furthermore, 
SCS has been tried, successfully, for orthostatic tremor175 and in a recent 
publication improvement of motor function in a patient with Parkinson’s disease 
with SCS was reported 77. 
 
1.4 SPINAL CORD STIMULATION – TECHNIQUE 
Originally the electrodes used for SCS were placed subdurally and anchored 
to the inner surface of the dura via a laminectomy. With time, cable electrodes 
were constructed, which could be implanted percutaneously, using a Tuohy-
needle, enabling a much more patient-friendly technique. Over time electrode 
configurations have evolved further.  Modern electrodes have up to 16 
individual contacts, allowing for stimulation more easily tailored to the 
individual patient. Both percutaneous techniques with cable-type electrodes and 
surgical implantations with plate-electrodes are in use, depending on patient 
needs and implanters’ preference. 
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Modern stimulators are fully implantable, with internal electronic circuitry 
and battery, producing either constant voltage or constant current stimulation. 
Typically stimulation is performed using square wave pulses in a frequency 
range between 30 and 70 Hz and using pulse widths ranging from about 210 to 
450 µsec. The stimulation intensity is set by the individual patient to a level 
yielding comfortable paresthesias covering the painful area and stimulation is 
turned on and off by the patient at will.  
A positioning of the electrode resulting in paresthesias covering the painful 
area appears to be necessary for a pain relieving effect240. The proper positioning 
of an electrode cannot be precisely deduced from the anatomical distribution of 
pain. Only the patient’s own report of the spread of paresthesias can confirm an 
optimal placement of the electrode. It is therefore difficult to obtain a good 
position of an electrode if the patient is not cooperable, e.g. is under general 
anesthesia. However general anesthesia is often unavoidable if more extensive 
surgery is necessary for implantation, as can be the case for plate electrodes. 
1.4.1 Implantation techniques 
1.4.1.1 Percutaneous technique – cable-type electrodes 
During the first years with SCS a need for testing a patient’s response before 
extensive surgery became apparent. One such technique was introduced in 1972 
by Hosobuchi et al., who tested the patient’s response to dorsal column 
stimulation using an electrode introduced into the spinal cord at the C1/2 
level137. Stimulation was however only performed during the surgical procedure. 
The technique was modified so that a cable-type electrode could be introduced 
into the epidural space through a Tuohy-needle and testing performed for a 
prolonged time period74. If the result of the testing was satisfactory a 
laminotomy electrode was implanted. Quite soon some implanters instead chose 
to retain the cable-type electrode and to utilize it permanently, only connecting it 
to an implantable pulse generator (IPG) after the trial period44,47. 
Typically, implantation of a percutaneous cable-type electrode is done in 
local anesthesia with the patient in the prone position, but a sitting position can 
also be used. Intraoperative fluoroscopy aides in locating a proper position of the 
electrode corroborated by the patient’s report of paresthesias perceived. Usually 
the Tuohy-needle is introduced in a paramedian oblique fashion some vertebral 
levels below the spinal level at which an optimal position is expected. 
Percutaneous implantation is the method of choice for the majority of SCS 
implanters, due to its ease of performance and minor infliction of surgically 
related pain. Evident draw-backs are, however, a possible need for higher 
stimulation amplitude as the electrode contacts are smaller, and a higher risk of 
electrode dislocation, especially at the cervical level247,248. 
1.4.1.2 Laminotomy technique – plate electrodes 
The original technique for implantation of an SCS electrode not only 
required a laminectomy, but also opening of the dura. This had the advantage of 
quite low current demand, but concerns with post-operative CSF leaks. The 
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technique evolved into usage of an epidural positioning of the electrode, 
eliminating the problem of CSF leaks. Even so the operation is associated with 
substantial operative and post-operative pain. The extent of removal of lamina 
and spinous processes necessary varies depending on the amount of epidural 
adhesions and if extensive removal is necessary the pain caused by the 
procedure will increase. In most cases only a minor laminotomy is necessary, 
but in a few cases laminectomy of several vertebral levels has to be performed. 
 Typically, the procedure is performed with the patient in the prone position 
under fluoroscopic control of the position of the electrode. The procedure can be 
done with the patient under general anesthesia, effectively diminishing operative 
pain but with the disadvantage of precluding intraoperative confirmation of a 
positioning of the electrode yielding paresthesias covering the painful area. 
Alternatively the procedure can be performed under local anesthesia, allowing 
for intra-operative control of adequate positioning, but with much more 
discomfort for the patient. 
For many implanters laminotomy electrodes are the first choice of technique 
based on a number of advantages. Laminotomy  (plate) electrodes (paddle leads) 
are typically larger and also insulated on the side not facing the dura resulting in 
lower current demand and wider paresthesia coverage247. Furthermore, the size 
generally makes the position of these electrodes in the epidural space more 
stable248. 
1.4.1.3 Implantation of IPG and connections 
A permanent SCS system also requires an implanted pulse generator (IPG) 
that can deliver current. There are many possible sites for placement of an IPG, 
such as the abdominal wall, the buttocks3, infraclavicularly or in the lateral 
lumbar region in the back232, close to the electrode insertion. Some expert 
groups favour the abdominal wall, based on more advantageous measurements 
of tensile load on the electrode and the connecting cable123,177, but the choice 
must anyway be based on the implanter’s experience and foremost on the 
patient’s preference. 
Depending on the electrode length and the position chosen for the IPG a 
connector cable is necessary in most cases. 
1.4.2 Electrode and stimulator design 
Electrical stimulation requires a negative and a positive contact for a closed 
circuit current. Initially, SCS electrodes either were monopolar with the cathode 
at the spinal cord and the anode elsewhere (harbored inside the IPG or in a 
different location, such as the thoracic wall) or bipolar with the negative and the 
positive contacts adjacent to each other on the electrode. Later, as a means to 
diminish the negative consequences of electrode dislocation or suboptimal initial 
electrode positioning, multipolar electrodes were produced. At first they 
included four contacts. These were distributed in line with each other for cable-
type electrodes and the spacing between electrodes varied between electrode 
types. For plate electrodes configurations with contacts in line as well as 
diamond shape were manufactured. 
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Modern electrodes have even more contacts, at present up to twenty, and 
with elaborate configurations for plate electrodes. 
The first IPGs were passive receivers relaying current produced by an 
external stimulator via an RF antenna. A clear advantage was that battery 
exchange was a minor problem, as they were not internalized in the patient. 
Battery exchange was as simple as for a transistor radio. Disadvantages were on 
the other hand that it was difficult to use this setup with multipolar electrodes. 
Furthermore patients often felt that the process of daily attaching the antenna to 
the skin at the stimulator site was cumbersome and skin reactions to the antenna 
or its adhesive were not uncommon. 
The next generation of IPGs has internalized batteries allowing more 
freedom for the patient. Using a remote control the patient can turn the 
stimulation on or off and increase or decrease the intensity of stimulation. 
Recent generations of IPGs allow for even more intricate control of the IPG 
function, with multi-programmable settings of stimulation parameters. The 
disadvantage of the battery-operated IPG is its limited capacity that eventually 
will lead to depletion and the need for replacement. As the battery is internalized 
an operative procedure is thus necessitated, in a few cases within an even shorter 
time-period than a year. 
The most recent development of IPGs has been the introduction of 
rechargeable IPGs. These have, as so many modern electrical appliances, 
rechargeable batteries and the patient will repeatedly recharge his/her battery 
through the skin. Even a rechargeable battery will need replacement eventually, 
but far less frequently than the non-rechargeable ones. As the more elaborate 
programming capabilities of recent generation IPGs drain battery power, 
rechargeable batteries are becoming more and more in use, despite higher cost 
and the necessity for the patient to recharge regularly. 
Figure 2: Contemporary electrodes and implantable pulse generators from three manufacturers of SCS systems: 
Medtronic (A), Boston Scientific (B) and Saint Jude Medical (C). 
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IPGs have also evolved into smaller size, imposing less discomfort to the 
patient at the implant site. Examples of contemporary electrodes and IPGs are 
given in Figure 2. 
1.4.3 Stimulation parameters 
The first SCS treatments were performed with variants of commercially 
available stimulators that were present at that time. Medtronic Inc. then 
manufactured two types of stimulators for carotid sinus stimulation, the Barostat 
(since 1963) for hypertension and the Angiostat (since 1965) for angina, which 
were modified95. The stimulator produced square wave pulses and the amplitude, 
the frequency and the pulse-width could be modified. Shealy et al state that 
during the pioneering early years of SCS other modes of stimulation were also 
tested, such as sine wave stimulation, triangular biphasic square wave 
stimulation and also increased frequency up to 2 000 Hz, with no improvement 
in pain relief299. 
Modern stimulators also allow for modification of frequency, pulse-width 
and amplitude yielding square wave pulses either with constant voltage or 
constant current. Settings are individually tried out to result in the spread of 
comfortable paresthesias in the painful area.  
Changes in pulse width can alter the spread of paresthesias, with higher 
pulse width often resulting in a wider spreading. Computer modeling and a 
patient trial suggest that a higher pulse width than 450 µs, however, will not 
result in further increase of covered area129. The increase in coverage with 
increased pulse-width may be the result of smaller nerve fibers being more 
easily recruited129 or, alternatively, that more deep-seated fibers in the dorsal 
columns are activated . 
 Variation of frequency has been tested in a study from 20101. Frequencies 
from 10 to 100 Hz were tried in increments of 10 in a study population of 72 
patients with SCS for various indications. As frequency increased the spread of 
paresthesias also did, but the quality of the paresthesias changed as well. The 
patients graded the quality of paresthesias on a 5-degree scale and the best score 
was achieved at 50 Hz.  
The amplitude is set by the patient to yield comfortable paresthesias. It is a 
common practice to determine, for the individual patient, the usage range. This 
is the range between the perception threshold and the discomfort level, i.e. the 
range from the lowest stimulation intensity that the patient can perceive and the 
highest stimulation intensity that the patient considers comfortable249. The 
patient also decides when to turn the stimulation on and off. The amount of time 
that the patient has the stimulation turned on varies individually, some patients 
only using stimulation occasionally, but most patients repeatedly every day and 
some patients continuously. No systematic study on the significance of 
stimulation time patterns has been published. 
1.4.4 Computer modeling 
With a knowledge of the electrical properties of the different tissues and 
fluids inside the spinal canal12 it is possible to set up computer models of current 
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spread and the resulting electrical impact on the spinal cord. This has been 
performed and reported since 1980 (Coburn)41 with increasingly better models 
presented over the years, especially by Holsheimer and collaborators126. Based 
on these models it has been possible to predict optimal electrode design in terms 
of contact spacing and configuration128,130-133 as well as stimulation 
parameters129. Computer models also help us to determine which neuronal 
structures that are primarily stimulated in clinical SCS, i.e. mainly axons in the 
dorsal columns127. 
1.5 SPINAL CORD STIMULATION – RESULTS 
Not all eligible patients respond to SCS in spite of adequate electrode 
positioning. Typically, the response to SCS is a pain reduction that usually 
outlasts the stimulation for up to an hour or more. Often a 50 % pain reduction is 
required for a neuropathic pain patient to be classified as a responder243. In 
Figure 3. A schematic diagram showing a lumbar slice of the spinal cord with SCS applied just rostrally 
to this level. The antidromic impulses generated in the dorsal columns activate inhibitory 
interneurons – among them some GABAergic which reduce the activation (and release of excitatory 
transmitters) of the hyperexcitable second order neurons and among these the WDR cells. Another 
major impulse path is orthodromic to the brain, activating circuitry in the brain stem ultimately giving 
rise to descending impulses via the dorsolateral funiculi (DLF) amplifying the inhibitory processes at 
the spinal level (Ach=acetylcholine, Aden=adenosine, 5‐HT=serotonin, DC=dorsal column, X=as yet 
unknown mediators). Reprinted, with permission, and slightly modified from Linderoth and 
Meyerson. Anesthesiology, 2010200. 
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neuropathic pain the responder rate may vary between 50 and 70 %, whereas it 
is higher for ischemic pain conditions, especially for angina pectoris. A 
characteristic feature of SCS is that in many cases a good pain relieving effect 
may persist for many years, even decades305. 
It is a common procedure to test the effect of SCS for a limited time period, 
such as 1- 4 weeks, before a decision is taken to fully implant a system243,245. 
Unfortunately a reduction of SCS effect may occur, even after several years of 
successful stimulation, as well as technical problems such as failure of a 
component in the SCS system or electrode dislocation.  
Among hardware related complications to SCS electrode migration is the 
most common and electrode breakage the second most common. In a meta-
analysis the risks were calculated to 13.2 % for dislocation and 9.1 % for 
breakage29. Dislocation may require electrode repositioning or even exchange of 
a cable-type electrode to a plate electrode, less prone to dislocate due to its larger 
size248. Other types of hard-ware related malfunction, such as battery failure 
(battery depletion due to intended use of SCS is not considered a complication) 
or loose connection were less common, in total about 4.9 %29. 
Other important complications are infections, with the risk estimated to 
3.4 % in a meta-analysis, and dural puncture, pain over implant, undesirable 
paresthesias, hematomas and seroma formation all of whom carry a low risk29. 
The risk of permanent spinal cord injury with persisting neurological deficits is 
very low, estimated to 0.03 %29. Formation of scarring around the electrode, 
causing spinal cord compression, has been reported in a few cases53,279,346. 
1.6 SPINAL CORD STIMULATION – MECHANISMS OF ACTION. 
The mechanisms of action of spinal cord stimulation are still incompletely 
understood. In order to elucidate the mechanisms underlying the pain relieving 
effects a number of studies have been published in the last 30 years, many of 
which emanate from the Karolinska laboratories195. Although some of these 
investigations have been performed on patients, most data have been collected 
from experiments on animals subjected to e.g. peripheral nerve injury or 
myocardial ischemia, i. e. mimicking known pathological conditions for which 
SCS treatment is used195. There is evidence that the mechanisms of action in 
neuropathic pain differ from those in ischemic pain225 (see Figure 3 for a 
schematic representation of putative mechanisms of SCS in the treatment of 
neuropathic pain) . Opioid mechanisms seem not to be involved, since injection 
of naloxone does not diminish the pain-relieving effect of SCS in humans87. 
When SCS has been tested in animal models of neuropathy it appears that 
like  human patients not all animals with signs of neuropathy respond to SCS195. 
The involvement of a number of neurotransmitters in the SCS effects has been 
explored and these levels have been correlated to the animals’ response to SCS. 
Further information has been gathered through administration of different 
receptor agonists or antagonists as well as other pharmaceutically active 
substances. There is good evidence that GABAergic49, serotonergic315 and 
cholinergic295 mechanisms are involved in the effect of SCS, predominantly 
mediated via GABAB, muscarinic M4 and a few identified serotonergic 
receptors. Furthermore, in these experiments a number of pharmacological 
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agents have been demonstrated to enhance the pain relieving effect of SCS, such 
as the GABAB-agonist baclofen49, the adenosine A1 receptor agonist R-PIA52, 
the α2-adrenoceptor agonist clonidine296, etc. It was also found that addition of 
one of these drugs, even in a per se ineffective dose, could convert a SCS non-
responsive animal into a responder. 
1.6.1 Human studies 
A number of studies to elucidate the underlying mechanisms have been 
presented, where patients with SCS have been investigated, utilizing e.g. sensory 
testing63,162,193,276,351, CSF sampling189,226,340, EEG328 and SEP257,268, functional 
magnetic resonance imaging (fMRI)167,277,320, transcranial Doppler flowmetry 
(TCD)40,284, transcranial magnetic stimulation (TMS)297 and PET168.   
1.6.2 Animal studies 
In the laboratory setting experiments have been executed both on intact 
animals and on animals subject to injuries and modifications mimicking 
pathological conditions195. Different types of spinal cord stimulation equipment 
modified to suit the experimental settings have been used. Experiments have 
been performed acutely, on anesthetized animals, as well as with miniature SCS 
systems chronically implanted in freely moving animals. Stimulation parameters 
used have varied extensively and in many cases they have been quite different to 
normal parameters used for human SCS, e.g. stimulation lasting only a few 
seconds.  
When experimental SCS has been used in an attempt to resemble clinical 
settings stimulation sessions of 20-30 minutes often have been utilized and 
stimulation amplitude frequently set to a percentage (e.g. 66, 80 or 90 %) of the 
intensity necessary for a motor response228. This may well correspond to 
stimulation intensities in humans. In a study, presented in 1980, Dimitrijevic et 
al reported both the perception threshold and the threshold for muscle twitches 
with SCS and the ratio was in average 77 %61. During awake stimulation in 
freely moving rats animals are reported to typically react to initiation of SCS 
with “a short disruption of their ongoing activities, but did not display signs of 
unpleasant sensations”321. This is in compliance with a perceivable but not 
disagreeable experience of the stimulation, just as clinical SCS. 
1.6.2.1 Animal studies in models of neuropathic pain 
For a better understanding of the mechanisms specific for the treatment of 
neuropathic pain experimental studies on nerve lesioned animals have been 
performed227. Frequently this has involved testing of sensitivity after a partial 
nerve lesion, making it possible to subdivide the animals into those showing 
withdrawal responses to normally innocuous sensory stimulation and those 
displaying normal reaction patterns. The former are often classified as 
“hypersensitive” or “allodynic” animals (since the pathological hypersensitivity 
resembles clinical allodynia as observed in some neuropathic patients). Sensory 
testing has involved e.g. von Frey filaments, focused radiant heat and cold spray 
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in animals moving freely, awake, inside a cage. In the vast majority of published 
experiments rats have been used.  
In a neurophysiological study of nerve injured rats the presence of dorsal 
horn (DH) neurons displaying increased spontaneous discharge, increased 
responsiveness to pressure and brush stroke and prolonged afterdischarge was 
noted, especially among animals classified as “allodynic”366. The position in the 
DH of each of the 140 neurons recorded in the study could not be determined, 
but when calculated from the recording probe depth it was concluded that they 
were situated in lamina III-V366. Specifically wide-dynamic range neurons 
(WDR, i.e. neurons showing increasing responses to many intensities of 
stimulation, such as brush►pressure►pinch) were tested. When SCS was 
applied a decrease of afterdischarge as well as a decrease of an exaggerated 
primary response appeared. In Figure 4 the responses of two individual WDR 
neurons in an “allodynic” animal to mild paw pressure before and after SCS are 
depicted. It is conceivable that this SCS response in animals could correspond to 
the effect SCS can have on pain and allodynia in humans112,225. The 
electrophysiological findings on SCS effects in the DH have been confirmed and 
explored further in a recent publication demonstrating that SCS can reduce DH 
neuronal excitability in nerve injured rats106. 
In experiments where SCS was applied and microdialysis of the DH was 
performed an increase of GABA and a reduction of the excitatory amino acids 
glutamate and aspartate could be demonstrated51. The GABA-effect appeared 
only in animals that also had responded to SCS with a suppression of the nerve 
Figure 4: An example of electrophysiological studies of SCS mechanisms showing responses 
to innocuous pressure in two separate dorsal horn neurons (A,B) in a nerve lesioned, 
hypersensitive “allodynic” rat. The bottom histograms show responses before SCS. 
Horizontal bars under the histograms indicate the duration of the innocuous pressure 
applied to the paw. Reprinted, with permission, from Yakhnitsa et al. Pain, 1999.366. 
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lesion induced hypersensitivity in the hind paw322. Since it has been observed 
that GABA may decrease in the spinal cord after peripheral nerve injury32, a 
finding confirmed also using microdialysis that assessed the extracellular GABA 
release, it seems reasonable that one mechanism of action for SCS may be a 
restoration of GABA levels in the DH. In a recent study it has been shown that 
in nerve injured rats responding to SCS an immediate decrease in intracellular 
GABA-immunoreactivity in DH neurons appears after SCS142. Furthermore it 
has been shown, by double-fluorescence of C-Fos and GABA, that SCS induced 
activation of GABA-immunoreactive cells142.  
The effect of pharmaceuticals acting on GABA-receptors has also been 
explored experimentally and it has been shown that i.t. injection of a GABAB 
antagonist could abolish the SCS effect on tactile “allodynia” in neuropathic 
animals; bicuculline (a GABAA antagonist) had a lesser effect49,51. When i.t. 
injections of baclofen (a GABAB-agonist) or GABA were used the effect of SCS 
was instead substantially enhanced, to an extent that even animals who had not 
responded to SCS could be converted to responders with an i.t. dose of baclofen 
so low that it did not by itself demonstrate any effect49. In a similar way it has 
been shown that R-PIA (an adenosine A1-receptor agonist) also can enhance the 
effect of SCS and even turn SCS non-responding animals into responders, with a 
per se sub-effective dose50,52. 
The role of acetylcholine (Ach) has also been explored in conjunction with 
SCS. Using microdialysis in the DH it was demonstrated that animals 
responding to SCS exhibited an increase in the release of Ach as a result of SCS, 
whereas this did not appear in non-responding animals295. I.t. administration of 
nicotinic and muscarinic Ach receptor antagonist revealed that M4 and M2 
receptors were essential for the SCS-effect and an immunohistochemical study 
has supported the importance of the M4 receptor for the SCS response in 
animals that were subject to peripheral nerve injury313. Administration of a 
muscarinic receptor agonist (oxotremorine) i.t. exhibited a dose-dependent 
Figure 5. An example of experimental results demonstrating enhancing effect of i.t. medication 
on SCS effect. The graphs show withdrawal thresholds to tactile stimulation during and after 
SCS with or without concomitant i.t. administration of clonidine (in an individually 
predetermined subeffective dose). Reprinted, with permission, from Schechtmann et al. 
Anesth Analg, 2004 296. 
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suppression of tactile hypersensitivity and an enhancement of SCS effects. 
Combining a subeffective dose of oxotremorine with SCS induced a substantial 
improvement of the SCS effect, a result appearing even in animals that had not 
at first displayed any appreciable treatment effect with SCS alone313. 
Levels of serotonin in the DH have been measured in rats both on the 
ipsilateral and the contralateral side to an induced nerve injury315. Serotonin 
appeared to increase in the ipsilateral DH as a result of SCS and only in those 
animals that had previously responded to SCS with normalized withdrawal 
threshold but not in the animals that despite an “allodynic” result of nerve injury 
did not respond to SCS. Furthermore, it was shown that a combined treatment 
with SCS and i.t. delivery of a low dose of serotonin (that in itself exerted no 
effect) could render an animal not responsive to SCS a clear responder315. 
Clonidine, an adrenergic alpha-2 receptor agonist mainly used for treatment 
of hypertension, has evolved to be used for pain treatment as well. Cholinergic 
mechanisms seem to be involved in the pain reducing effects of 
clonidine250,255,256, possibly also involving nitric oxide (NO) transmission365. I.t. 
clonidine has also been tested together with SCS and it has been shown that it 
can enhance the effect of SCS, using a dose lower than the dose necessary for 
clonidine to produce an effect on the withdrawal threshold by itself (Fig 5)296. 
 Animal experiments with SCS and i.t. pharmaceutical agents have also been 
performed with the anticonvulsants pregabalin and gabapentin, drugs that are 
frequently used for peroral treatment of neuropathic pain. Both drugs could 
produce a reduction of the hypersensitivity from experimental nerve injury, in a 
dose-dependent manner and a subeffective dose could, used together with SCS, 
augment the effect of SCS and even turn a SCS non-responding animal into a 
responder348. 
Another group of pharmaceuticals with important use in the treatment of 
neuropathic pain, namely antidepressants, have also been studied in animal 
experiments exploring SCS effects312. Doses subeffective for a drug effect on 
pain behavior per se were administered i.t. concomitantly with SCS. Of the 
drugs tested, amitryptilin (a tricyclic antidepressant) and milnacipran (a dual 
serotonin/noradrenalin reuptake inhibitor) were shown to enhance the effect of 
SCS on the withdrawal threshold. In consideration of the previously mentioned 
cholinergic mechanisms involved in SCS the effect of amitryptilin would appear 
unexpected, since it is a drug with well-known cholinergic side effects. As for 
the third drug tested, fluoxetine (a selective serotonin reuptake inhibitor) no 
impact on the effect of SCS could be detected, with the doses used. 
It has been suggested that one of the glutamate receptors, n-methyl-d-
aspartate (NMDA) is involved in the central sensitization associated with 
neuropathic pain231,362. Based on this animal experiments using individually 
titrated sub-effective doses of i.t. ketamine (an NMDA receptor antagonist) 
concomitantly with SCS have been performed showing a potential for ketamine 
to transform a non-responding animal into a responder343. 
SCS does not only operate via spinal segmental effects but its mode of 
action also involves supraspinal mechanisms. In an experimental setting 
transection of the dorsal columns between an examined spinal level and a more 
rostrally applied SCS does not abolish the SCS effect11,288. In a series of 
experiments, a supraspinal loop, going from the dorsal columns to the brainstem 
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and back to the spinal cord, has been implicated in the effects of SCS72,287,288. 
This loop may well, but not exclusively, involve the nucleus raphe magnus. The 
previously mentioned experiments concerning serotonin release as a result of 
SCS also support a supraspinal influence on SCS effect, since serotonin in the 
spinal cord is of supra-spinal origin315. 
1.6.2.2 Animal studies in models of ischemic pain 
It is unlikely that the effect of SCS on ischemic pain predominately is a 
result of a reduction of pain generation and transmission225. An improved 
balance between tissue demand and supply of oxygen is more likely the reason 
for the reduction of ischemic pain by SCS197. An important factor seems to be an 
SCS-induced reduction of sympathetic activity and the effect of SCS on blood 
flow has been shown to be abolished if a sympathectomy had been performed198. 
Antidromic activiation with release of vasoactive substances, such as CGRP 
(calcitonin gene-related peptide) has also been implicated in the effect of SCS333. 
SCS may not only result in an increased oxygen supply, but might also reduce 
the tissue demand. In a study on skin flaps to which the arterial supply was 
occluded the survival was substantially improved if the animal had been 
pretreated with SCS94. 
1.6.2.3 Animal studies in models of bowel disorders 
A few animal studies on SCS mechanisms demonstrate effects on the 
gastrointestinal system, pertinent to IBS. One publication, from 2003, concerns 
the visceromotor response (VMR – measured by a strain gauge force transducer 
to the external oblique muscle) to balloon distention of the distal portion of the 
bowel102. It was shown that SCS, in settings corresponding to its clinical use, 
markedly reduced the VMR (see Figure 6). This reduction was maintained even 
after cessation of SCS, for more than an hour. If animals had been pretreated 
with a slow low concentration intracolonic acetic acid infusion a sensitization 
occurred, resulting in a marked VMR to an otherwise innocuous distension. SCS 
abolished this reaction completely. These results are of importance for IBS 
treatment, as it has been shown that IBS patients have lower thresholds to 
distension for pain, discomfort and perception in the distal colon as well as in the 
rectum and the oesophagus283,342.  
In another study, from 2005, an animal model of post-inflammatory colonic 
hypersensitivity was used. An enema of trinitrobenzenesulfonic acid was given 
and thirty days later, when the mucosa was normalized, a pronounced reaction to 
colonic distention remained. SCS, however, normalized this reaction103. Again 
these results are important for IBS-treatment, as there is an increased risk of 
developing IBS after gastroenteritis286. 
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In animal studies SCS has been shown to influence the transmission of 
visceroreceptor information in the spinal cord270,271. Qin et al have presented 
experiments where extra-cellular signaling from 28 single spinal neurons was 
recorded in the rat L6-S2 spinal segments. For a number of the neurons that 
responded to colorectal distention the response was inhibited by SCS both at the 
L2-L3 level and at the C1-C2 level. Furthermore, this inhibition was maintained 
after spinal cord transection of the cervicomedullary junction, but the effect of 
the C1-C2 SCS was abolished by transaction of the dorsal columns at the C7-C8 
level. At the end of each recording an electrolytic lesion was performed allowing 
for localization of the neurons. The responding neurons were found to be located 
in laminae I–III, VI, VII and X. A neurophysiological substrate for the SCS 
effect on the reaction to colonic dilatation has thus been demonstrated, similar to 
the effect SCS has been shown to exert on WDR cells in the experiments of SCS 
for neuropathic pain106,366. 
Figure 6. An example of the effect of SCS on the viscero‐motor response, VMR, to 
distension of a balloon in the colon to 60 mm Hg. After three consecutive 10 minute 
distensions a 30 minute SCS session (90 % motor threshold) was performed and followed 
by an additional 10 minute balloon distension. Reprinted, with permission, from 
Greenwood‐Van Meerveld et al. Auton Neurosci, 2003102. 
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2 AIMS OF THE THESIS 
The general aim of the studies in this thesis is to improve the use of spinal 
cord stimulation in humans with pain, specifically building, for Studies I-III and 
V, on the results from previous experimental studies in animals. A major part of 
the thesis thus exemplifies translational research “from bench to bedside”. 
2.1 STUDIES I-III: PHARMACOLOGICAL ENHANCEMENT OF SCS 
EFFECT 
To investigate if the beneficial enhancement of SCS effects that has been 
demonstrated in animal experiments with baclofen (study I and III), adenosine 
(study I) and clonidine (study III) also can be reproduced in human patients.  
To explore if this can be used to increase and/or restore the effect of SCS for 
patients with neuropathic pain, if the stimulation does not yield an optimal 
treatment result. 
To verify if a beneficial effect of pharmaceutical enhancement of SCS will 
remain over time (study II). 
2.2 STUDY IV: TECHNICAL IMPROVEMENT OF SCS 
To investigate if implantation of plate electrodes by laminotomy can be 
performed without discomfort using spinal anesthesia but still retaining the 
patient’s ability to experience and report paresthesias. 
2.3 STUDY V: NEW INDICATION FOR SCS 
To test if a different painful indication, namely IBS, can be effectively 
treated with SCS, again based on previous promising results in animal 
experiments. 
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3 MATERIALS AND METHODS 
3.1 PATIENTS 
3.1.1 Study I 
43 patients with neuropathic pain participated in a trial with SCS combined 
with intrathecal (i.t.) bolus administration of baclofen or adenosin. 35 of these 
patients were new to spinal cord stimulation, but during the test stimulation 
period they either had insufficient pain reduction (less than 50 %) or a 
poststimulatory pain reduction (after 30-40 min session of SCS) lasting for less 
than 45 minutes (or both). Eight patients had previously obtained SCS with good 
effect, but had experienced a diminishing pain relief with time. Five more 
patients were tested with i.t. drug administration only. They had either had SCS 
earlier but had had their equipment removed (3 patients, unwilling to receive 
new implants) or were unsuitable for SCS due to previous extensive spinal 
surgery (2 patients). 
Average age at the time of the trial was 51 years (range 25-75 years), 16 
men and 32 women. 
3.1.2 Study II 
Nine patients from study I, i.e. the remaining five patients having both an 
SCS-system and a pump for i.t. drug delivery pump and the four patients who 
were implanted with a pump only. 
3.1.3 Study III 
Ten patients with neuropathic pain were recruited. As in study I the patients 
either had used SCS for some time (in average 8 years; range 0.6-15 years), with 
intended effect initially, but diminishing pain relief over time (nine patients) or 
with insufficient pain reduction during test stimulation with a temporary 
electrode (one patient). For inclusion in the study the present situation should be, 
as in study I, that the pain reduction from SCS was less than 50 % as compared 
to baseline or that the pain reduction did not outlast cessation of a 30 to 40 
minutes long session of SCS (or both) with ≥ 45 minutes. Patients with 1) mental 
disability or other communication problems, 2) ongoing infection, 3) CNS 
disease, 4) heart disease and other vascular disease or 5) ongoing medication with 
which clonidine or baclofen can interact were excluded from the trial. 
Average age was 56 years (range 39-68 years), 5 men and 5 women. 
3.1.4 Study IV 
This is a retrospective study of twenty consecutive procedures with 
implantation of plate electrodes in spinal anesthesia, of which 18 were new 
implants and 2 (plate electrode) replacements. All patients had neuropathic pain 
that had been successfully treated with SCS using standard cable-type electrodes 
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in the low thoracic region. Due to repeated dislocations and/or inadequate 
paresthesia coverage implant of a plate electrode had been suggested, a common 
routine in these circumstances.  
Average age was 48 years (range 23-67 years), 7 men and 12 women. 
3.1.5 Study V 
Ten patients with IBS were recruited. Patients had a definite diagnosis of 
IBS according to Rome II criteria (Table 2)335. They were to have abdominal 
pain that, at least episodically, reached more than 4 on a 0-10 VAS scale and the 
symptoms should have been stable during the past 2 years. Patients were not to 
have, at the time of inclusion, other significant somatic or psychiatric illnesses. 
Routine blood and electrolyte samples, hepatic laboratory test, coloscopy or 
colon x-ray as well as lactose tolerance test were performed. 
Average age was 39 years (range 26-56 years), 3 men and 7 women. 
3.2 EQUIPMENT 
3.2.1 Lumbar puncture 
For lumbar punctures (Studies I and III) thin pencil-point needles (27 G, 
O.D.: 0.4 mm, Whitacre spinal set, USA) were used. By using a non-cutting 
thin blunt point the risk for post-dural puncture headache was expected to 
diminish. This claim is supported both by experimental findings134 as well as 
several randomized trials81,184,186,258 and long-time general experience. The 
pencil-point needles were introduced by Hart and Whitacre in October 1951114, 
based on ideas presented by Greene already in 1926101. Historically the blunt 
needle tip lumbar puncture needle was actually first presented by Sixten 
Haraldsson in May 1951, with a design quite similar to that of the Whitacre 
needle109. 
3.2.2 Implants 
3.2.2.1 SCS equipment 
In Studies I and III different types of SCS equipment were used (Figure 7) 
involving bipolar test electrodes, 4- and 8-polar cable type leads (Quad® and 
Octad®) as well as plate electrodes (Resume®). Implanted electrodes were 
Diagnostic criteria  for IBS (Rome II) 
At least 12 weeks, which need not be consecutive, 
in the preceding 12 months of abdominal 
discomfort or pain that has two of three features: 
(1) Relieved with defecation. 
(2) Onset associated with a change in 
frequency of stool. 
(3) Onset associated with a change in form 
(appearance) of stool. 
Table 2: Diagnostic criteria for IBS, 
Rome II 
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connected to implantable pulse generators, IPGs, Itrel 3®, Itrel 2®, Synergy® 
or Xtrel® (all manufactured by Medtronic Inc.). 
In Study IV either plate electrode Resume® or Symmix® (Medtronic Inc.) 
were utilized. 
In Study V patients were operated with cable type electrodes with wide 
spacing, Quad Plus®, and IPG Itrel 3® (Medtronic Inc.). 
3.2.2.2 Pumps for intrathecal drug administration 
In Study I Synchromed® pumps (Medtronic Inc) were implanted for i.t. 
baclofen administration. Synchromed® pumps are designed for slow 
continuous drug delivery and have been in use for treatment of spasticity since 
1985. For administration of adenosine Algomed® pumps (Medtronic Inc.) 
were used. These are subcutaneous patient-operated pumps enabling the 
individual patient to perform bolus infusions of 1 ml at his/her discretion. 
Bolus delivery is important for adenosine as it is rapidly metabolized, making 
this kind of pump suitable for adenosine administration. 
In Study III pump implants were Synchromed II® (Medtronic Inc.), a 
newer more slender version of the Synchromed pumps used in Study I 
(Figure 8). 
Figure 7. Various SCS implants used in the 
studies photographed on a background of 1 
cm x 1 cm grey squares. A: Itrel‐3®. B: 
Resume®. C: Symmix®. D: Quad‐plus®. 
Figure 8: Pump implant, Synchromed 
II®, photographed on a background 
of 1 cm x 1 cm grey squares. 
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3.2.3 Pharmaceutical agents 
3.2.3.1 Baclofen 
Baclofen (Figure 9) was first synthesized in 1962 and was used for peroral 
treatment of spasticity. It acts on the GABAB-receptor367. GABA (Figure 9) is 
the foremost inhibitory transmitter of the mammalian brain and one has 
estimated that about 40 % of synapses in the central nervous system are 
GABAergic367. GABA does not penetrate the blood-brain barrier, which 
baclofen does to some extent. In animal studies CSF concentration is about 10 % 
of that in plasma290 and in a human study quite variable, but low (≤10-20 %)171. 
By administering baclofen directly into the spinal canal much higher 
concentrations can be achieved260. In 1978 an animal study on i.t. baclofen was 
presented, showing an antinociceptive effect358. Later, in 1984, it was reported 
that i.t. baclofen could reduce spasticity in an animal model176 and in humans259. 
Pumps for continuous i.t. administration were being developed in the early 
1980ies, initially for opiate treatment of cancer pain252,261, and soon studies on 
i.t. baclofen administration via implantable pumps were presented260,262. Since 
then i.t. baclofen therapy has been used for spasticity with abundant 
experience25,138,251, and also for pain307. It is clear that the individual response is 
variable and it is customary to assess the individual response by single injection 
before pump implant. Already in one of the earliest studies the doses 25, 50 and 
75 µg were used for this purpose262. These are the doses our clinic has been 
using for screening of spasticity patients and therefore we chose these doses for 
our studies of i.t. baclofen as adjunct to SCS. 
Side-effects of i.t. baclofen include dizziness, muscular hypotonia, 
drowsiness as well as constipation and overdose can cause respiratory 
depression, coma and death138. There is no specific antidote to baclofen for 
human use, but increasing cholinergic transmission by i.v. administration of 
physostigmin has been recommended if serious symptoms of overdose 
appears237. Present recommendations, however, mainly emphasize stopping the 
pump, replacing its baclofen content with saline solution (in severe cases CSF 
withdrawal) and continued monitoring and supportive care (including ventilator 
support) in an intensive care setting353. Sudden withdrawal of baclofen may also 
be dangerous, with the possibility of severe reactions, including severe 
aggravation of spasticity138. Deaths have been reported100. 
Figure 9: Structural formulas of 
baclofen and GABA 
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3.2.3.2 Adenosine 
Adenosine (Figure 10) is an endogenous compound, found both intra- and 
extracellularly85. Adenosine receptors are widespread and found throughout the 
body with high concentration in the brain, dorsal horn of spinal cord, spleen, 
thymus, colon, heart, platelets and lymphocytes amongst other regions86. 
Adenosine thus affects a number of biological processes, including the immune 
system, but its main clinical use has been, since the 1980ies, within the field of 
cardiology116. Adenosine, however, has important effects on pain processing and 
animal experiments have shown reduction of pain behavior with i.t. 
adenosine293,316, especially with a neurogenic pain model317. It has also been 
reported that levels of blood and CSF adenosine is lower for patients with 
neuropathic pain than for controls107. In a case report from 1994 a patient with 
sural neuropathy and severe allodynia to touch and vibration was free from 
spontaneous pain for 10 days and from allodynia for over six months following 
an i.t. injection of the adenosine receptor A1 agonist R-PIA153. Adenosine has 
been explored for human i.t. use in a number of studies, in volunteers67,70,273, in 
pain patients16,71,311 and as an adjunct in anesthesiological practice16,71,274,275,311. 
Exogenous adenosine has a very rapid turnover both in plasma22 and CSF273, 
half-life within 10-20 minutes . Side-effects are mainly local lumbal pain at the 
level of injection and headache. The doses of adenosine in Study I were the 
same as in a parallel study in volunteers, referred to above273: 500 µg, 1 000 µg 
and 2 000 µg. 
3.2.3.3 Clonidine 
Clonidine (Figure 11) has been in use for treatment of hypertension since 
1966143. It is an adrenergic alpha-2 receptor agonist104, for which several other 
uses have evolved, such as pain treatment and opiate withdrawal symptoms143. 
Already in 1949 an analgesic effect of adrenalin was presented188 and in 1974 
animal experimental data indicated an antinociceptive effect of clonidine, both 
when administered intraperitoneally and in the lateral ventricle298. An 
involvement of cholinergic mechanisms in the pain-reducing effect of clonidine 
was reported already in 1980201, a notion supported by a number of publications 
since135,250,255,256,365. In 1984 Tamsen and Gordh reported that epidurally 
Figure 10: Structural formula of adenosine 
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administered clonidine could have analgetic action in man and a potentiating 
effect on coadministered epidural morphine332. Coombs et al reported in 1985 on 
the successful use of clonidine i.t. alone as a treatment for cancer pain in a 
patient with morphine tolerance48. Over the ensuing years numerous publications 
supporting the use of i.t. clonidine have appeared, either as a single treatment or 
in combination with other drugs8,62,80,117. Elimination half-life i.t. has been 
studied in sheep, yielding a value of in average 64 minutes33. There are no 
human studies on elimination after i.t. injection, but after epidural injection 
average half-life of clonidine in the CSF has been reported to be 66 minutes98. 
Side-effects of i.t. clonidine include hypotension, malaise, headache, confusion 
and lethargy117. In published trials doses for single i.t. injections varying from 15 
µg to 450 µg have been used8,62,79. We have chosen the doses 25, 50 and 75 µg 
for the bolus trials in Study III. In the first two cases a 100 µg dose was used, but 
this was abandoned as one patient demonstrated hypotension. 
3.2.3.4 Bupivacaine 
Bupivacaine (Figure 12) was synthesized in the late 50ies by the Swedish 
company Bofors and was introduced in clinical practice in the mid 1960ies187, 
188. Its foremost advantage was a long-lasting anesthetic effect, however 
accompanied by a higher toxicity. It came into abundant use, also for i.t. 
administration324. Serious side-effects of spinal anesthesia are uncommon, but 
include neurologic injuries, seizures, hypotension and cardiac arrest6. Several 
reports concerning increased risk for cardiac arrest with bupivacaine have been 
published, but no such increased risk could be seen in a very large French study 
summarizing the results of >40 000 spinal anesthesias6. The doses used in 
Figure 11: Structural formula of clonidine 
Figure 12: Structural formula of bupivacaine 
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Study IV were decided individually by the anesthesiologist in charge and were 
in accordance with current guidelines18. 
3.3 STUDY OUTLINES 
3.3.1 Study I 
On separate days single doses of Baclofen (25-75 µg, on some occasions 
100 µg) or placebo (saline) were injected via lumbar puncture in a single-blinded 
fashion, the first dose always being 25 µg, to check for side-effects, and higher 
doses in random order. Patients evaluated pain on a VAS scale (10 cm) at 
baseline and again after 30, 60 and 90 minutes. At 90 minutes after the injection 
of i.t. drug a 30 min session of SCS was started, after which patients recorded 
pain again. Patients were also asked to record for how long the SCS-effect 
lasted, if such was present, as well as any side-effects. A pain reduction of at 
least 50 %, with either i.t. drug or SCS or both, was considered a positive 
response, with only spontaneously appearing pain being assessed. 
A separate testing of adenosine was performed in a similar manner in a 
subset of patients (seven patients) (bolus doses of 500, 1000 or 2000 µg). In this 
procedure, however, SCS was started already after 30 minutes. Apart from this 
the procedure and pain assessment was the same as for baclofen. 
If i.t. drug administration substantially improved the effect of SCS patients 
were offered implantation of a pump for i.t. drug delivery as well as an SCS 
system. If the pain reduction was foremost attributed to the i.t. drug implantation 
of only a pump was suggested. For a few patients with exceptionally good 
response to a low dose of a drug, peroral drug administration was tried, as an 
adjunct to SCS. 
Follow-up investigation was performed on all patients who continued to use 
baclofen, either i.t. or perorally, with or without SCS. Patients were contacted 
for telephone interviews, utilizing a structured protocol (Table 3) and hospital 
records were reviewed for dosages, reoperations and adverse events. Follow-up 
was performed in average 30 months after pump implantation (or after initiation 
of medication for the three patients receiving per-oral baclofen), range 1-72 
months. 
3.3.2 Study II 
The second study constituted a late follow-up of all patients with remaining 
pumps at the end of Study I. Again structured telephone interviews were 
performed, with the same protocol as for Study I (table 3). Follow-up was 
performed at in average 67 months after pump implant, range 37-103 months. 
Hospital records were also reviewed for present dosages, reoperation etc. until in 
average 73 months, range 45-111 months. 
3.3.3 Study III 
On separate days single injections of baclofen (doses 25, 50 and 75 µg), 
clonidine (25, 50 and 75 µg – in two cases instead 100 µg) or placebo were 
 32 
injected via lumbar puncture in a double-blinded randomized fashion. 
Randomization had been set up so that the first dose of a drug always was 25 µg, 
but higher doses appeared in random order. Two placebo injections were 
interspersed among the active drug injections. As in Study I patients assessed 
pain baseline and then every 30 minutes and a 30 minute SCS session was 
started 90 minutes after the i.t. injection. A pain reduction of at least 30 %, with 
either i.t. drug or SCS or both, was considered a positive response, with only 
spontaneous pain being assessed. Patients were urged to report side-effects. 
In case of a clear benefit from the combination of an i.t. drug and SCS 
implantation of a pump was recommended. Ambiguous responses were first 
rechecked with further injections, including placebo. 
Structured telephone interview protocol 
Interview questions 
1. Average VAS as experienced in the last 2-3 weeks 
before the interview 2. Minimum VAS 3. Maximum VAS 
4. Verbal pain assessment, average pain rating: 
0: pain free 
1: slight pain 
2: moderate pain 
3: strong pain (clear interference with ADL) 
4:  very strong pain 
5: extreme pain (totally disabling) 
5. Change of ADL as compared to before treatment: 
0: similar or worse than before implant 
1 somewhat improved 
2: clearly improved 
3: substantially improved 
4: normalized 
6. Side-effects? 
7. Would you have undergone this treatment if you had known the result 
in advance? Y/N 
8. Would you recommend this treatment to another patient/friend with 
similar problems? Y/N 
9. Global satisfaction score: 
0: Disappointed of treatment outcome 
1: Neither satisfied nor dissatisfied 
2: Satisfied 
3: Very satisfied  
10. Medication pre-implant? 
11. Present pain medication? 
12. Change in pain medication pre-implant to present: 
0: Increased medication 
1: Unchanged medication 
2: Decreased medication 
3: Substantially decreased medication 
4: No other pain medication than intrathecal baclofen   
Table 3: Structured interview protocol (Studies I‐III) 
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In Study III, as well, a follow-up was performed on the patients that received 
a pump, using the structured interview protocol from Studies I and II (table 3) 
and hospital record reviews.  
3.3.4 Study IV 
Patients undergoing scheduled implantations of a plate electrode in spinal 
anesthesia were interviewed regarding problems during surgery. Ease of 
performing operation, operative time, thresholds for paresthesias during surgery 
as well as in the prone position postoperatively, amounts of anesthetic agents 
and i.t. injection level were noted. 
At operations spinal anesthesia was induced via injection of bupivacaine 
(see section 3.2.3.4) at the L2/3 level. Supplementary local anesthetic was used 
at the site of incision. A small laminotomy was performed at the intended level, 
including part of the spinous process and the electrode was introduced into the 
epidural space. Intraoperatively testing for adequate paresthesias was performed 
utilizing a standard external stimulator (DualScreen®, Model 362, Medtronic 
Inc.). If paresthesias were not adequate repositioning of the electrode was carried 
out. Before closure the electrode position was checked with anteroposterior 
fluoroscopy. 
3.3.5 Study V 
Electrodes with widely spaced stimulating poles (Quad plus®, Medtronic 
Inc.) were percutaneously implanted at T11/12 and positioned to yield 
paresthesias in the abdominal area (with or without paresthesias in the lower 
extremities), with the tip of the electrode at the T5-T8 level. According to the 
protocol patients did not use stimulation the first 2 weeks after surgery. They 
were then randomized to either start a 6 week period with stimulation or a 6 
week period without. At the end of these six weeks, patients crossed over to not 
stimulate for another six weeks or vice versa. Subsequently, all patients 
continued with a 12 week long period of stimulation (Figure 13 illustrates the 
Figure 13: Flow chart for the SCS‐IBS study (Study V) 
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trial outline). During periods of stimulation patients turned the stimulation on or 
off at will, but were instructed to stimulate at least 8-12 hours out of 24, with a 
comfortable intensity and preferably at least 12 hours. Compliance was checked 
from the implanted stimulator memory at regular out-patient visits. Participants 
noted daily 1) number of pain attacks during the day, 2) number of diarrheas 
during the day, 3) average pain level during the day and 4) average evaluation of 
quality of life (QOL). For items 3 and 4 patients were asked to utilize a numeric 
rating scale from 0-10 (10 implying worst possible pain or best possible quality 
of life respectively). At the end of the study patients could choose to keep the 
stimulating system or have it removed. 
All patients were contacted for follow-up at the end of the study using a 
structured telephone interview. Among questions asked were present pain level, 
usage of stimulation system (if present), medication, side-effects and global 
satisfaction. Each patient was also evaluated using a Swedish version of the 
hospital anxiety and depression scale (HAD)370 and a modified gastrointestinal 
symptom rating scale (GSRS-IBS)355. 
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4 RESULTS 
4.1 STUDY I 
Twenty patients responded to Baclofen, either in combination with SCS (16 
patients) or baclofen alone (4 patients). These patients were offered continued 
baclofen treatment with i.t. (with an implantable pump) or oral administration 
(the oral route was offered to those who had an exceptionally good response to 
baclofen at the lowest i.t. dose, 25 µg) either with SCS or with the drug alone (if 
SCS was not possible). Seven patients received a baclofen pump as an adjunct to 
SCS, and four patients received pumps for i.t. drug delivery alone, without SCS. 
In two of the seven patients with SCS and i.t. drug treatment, the pumps had to 
be explanted due to technical problems and diminished pain relieving effect. 
Two patients opted for i.t. administration of adenosine, requiring a different 
type of pump that does not yield a constant flow, but has a patient operated 
mechanism for single boluses. Delivering adenosine by this pump unfortunately 
did not function satisfactorily. Due to side effects, back-pain and headache, a 
local anesthetic had to be coadministered with the adenosine solution. This 
mixture was, however, not stable in the pump and most of the pain relieving 
effect was lost within a week. One patient with such a pump chose to have it 
removed and eventually all adenosine treatments were terminated (within ≈ 1 
year). 
Follow-up on the patients with baclofen was performed in average 30 
months after implant using a formal telephone interview protocol. The patients 
with SCS + i.t. baclofen reported a drop in VAS from 76 (70-90) before the 
bolus trials to 33 (0-80) at follow-up. The patients with SCS and peroral 
medication reduced the pre-trial VAS from 70 to 27 whereas the patients with 
i.t. baclofen alone reported a reduction from 63 (40-90) to 33 (20-80). During 
the follow-up period the baclofen dose had to be increased in all patients from an 
average of 72 µg/24 h to 157 µg/24 h. 
4.2 STUDY II 
Patients reported some increase in pain as compared to the early follow-up, 
but still it was significantly lower than the pre-trial values. In most patients it 
was necessary to further increase the baclofen dose by in average 30 % 
compared to the early follow-up. A number of surgical interventions had been  
necessary (four exchanges of pumps due to battery depletion, one replacement of 
a fractured i.t. catheter, seven exchanges of SCS stimulators and three SCS 
electrode revisions); nonetheless, all patients continued to use the treatment and 
wanted to keep it. 
4.3 STUDY III 
For both drugs a significant dose dependant enhancement of pain reduction 
was recorded. Five patients were deemed as clear responders and four of them 
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chose to have a pump implanted. Based upon individual patient response two 
pumps were used for administration of baclofen and two pumps for clonidine. 
4.4 STUDY IV 
In all patients a complete analgesia could be achieved, using bolus injections 
of 12.5 to 20 mg bupivacaine, and a small laminotomy performed at the T9/10, 
T10/11 or T11/12 level. For one patient it was necessary to perform a second i.t. 
injection. A plate electrode was introduced and tested intraoperatively, and in all 
cases paresthesias could be produced, in several instances resulting in a 
repositioning of the electrode. For all patients an optimal paresthesia coverage 
could be achieved. Operative times were between 70 and 195 minutes, in 
average 112 minutes. The thresholds for paresthesias during operation were 
similar or only slightly higher than thresholds recorded after surgery when tested 
in the same supine position (mean 3.1 V during surgery and 2.1 V after surgery). 
At interview after surgery none of the patients reported that the interventions had 
been painful or uncomfortable. 
4.5 STUDY V  
One patient chose to leave the study after ten weeks and her SCS system 
was removed. The remaining nine patients completed the entire study. Three 
patients did not achieve any benefits from stimulation and chose to have their 
SCS-system removed. Six of the participants reported a satisfactory result with 
stimulation and have continued the stimulation treatment beyond the trial period. 
Periods with stimulation were compared to periods without stimulation. Pain 
scores as well as number of pain attacks and diarrhea episodes daily were lower 
during stimulation periods than during non-stimulation, but only the difference 
in pain scores reached statistical significance (p=0.04). The differences for the 
other parameters were not significant and for quality of life measurement no 
differences could be detected. 
On follow-up half of the patients who had decided to keep their stimulation 
stated that they still used it. For two of the patients who had ceased to use it a 
gradual decrease of pain had appeared over the years to a degree that they had 
chosen not to use it. They kept the stimulation system anyhow, in case pain 
would recur. One patient had to have the equipment removed, due to need for an 
MRI scan. 
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5 DISCUSSION 
5.1.1 Pharmacological enhancement of SCS effects 
These studies are entirely based on findings derived from experiments on 
animal models of neuropathic pain performed at the laboratory of the 
Department of Neurosurgery at the Karolinska University Hospital/Karolinska 
Institutet. Thus they are typical examples of a translational approach with a 
direct transfer of knowledge from “bench to bedside”. 
There are several limitations to the studies, most importantly the small 
number of patients. In Study I the injections were only single-blinded, but in the 
preparations for Study III it was decided to use double-blinded and randomized 
injections. In none of the studies SCS could be blinded to the patients, which is a 
limitation to almost all studies on SCS (compare section 1.3). Even with blinded 
testing of i.t. injections the comparison of results only concerns the outcomes of 
bolus injections, not the long-term results. For a decisive investigation of the 
long-term usefulness of adding i.t. drug delivery to suboptimally acting SCS a 
proper (randomized) control group with SCS but no pump should be included 
(or better pump with saline and periods with active drug). The protocol for 
follow-up telephone interviews is not validated, but it was considered that 
comparisons could be facilitated if the same protocol was utilized. The usage of 
telephone interviews implies that an NRS scale has been employed, but it has 
been inappropriately named VAS in the publications. There are, however, some 
studies indicating a fair correspondence between VAS and NRS78,269 implying 
that this practice is acceptable.  
Based on the laboratory findings on the pivotal role of the GABAB-receptor 
in the SCS effect49-52 it was logical to start investigating the possibility of 
enhancing the response to SCS with i.t. drug delivery of baclofen since it is a 
drug already registered for i.t. use, accompanied with a substantial clinical 
experience. This not only facilitated ethical approval, but also general handling 
of the patients concerning dosages, side effects, etc. The choice to continue with 
clonidine (strongly supported by both the animal findings with SCS enhanced by 
clonidine296 and by the importance of cholinergic mechanisms in SCS295) was 
also based on the fact that an abundance of clinical experience – manifested 
through a number of scientific publications – existed as to its use as an i.t. 
treatment. The use of clonidine i.t. is, however, off-label, and, at least in Sweden 
where the studies took place, an individual approval from a state authority 
(Swedish Medical Products Agency) was necessary for continued treatment with 
i.t. clonidine for each patient receiving a pump. The results from Study I were 
unfavorable for adenosine and no further attempts to explore adenosine i.t. in 
continued bolus administration, via an implanted pump, seem reasonable until a 
solution to the side effects with low-back pain has been established. 
In none of the trials reported in these studies (I-III) it was possible to convert 
a patient who showed no response to SCS into a responder. This is in contrast to 
the results of the preceding animal studies50,296, where a non-responding animal 
could be transformed into a responder with a dose of an i.t. drug that in itself 
was without effect. The animal models are, however, models of reactions 
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associated with neuropathic pain. All testing in animals subjected to nerve injury 
consisted of stimulus-induced pain-like behavior, i.e. evoked pain, whereas in 
practically all the human studies only ongoing spontaneous pain was assessed. A 
notable concern here is that only 20-40 %, at most, of neuropathic pain patients 
present with mechanical allodynia108. Only in a study from 2004, Harke et al. 
reported SCS effects on both spontaneous pain and allodynia112. Or obvious 
reasons it is difficult to know if experimental animals suffer spontaneous 
ongoing pain after nerve injury because they rarely exhibit behavioral changes 
that may be interpreted as indicative of pain. It has also been debated if 
behavioral changes after nerve injury, such as holding a paw in a protected 
position, necessarily reflect ongoing pain196,233,354. Not only sensory but also 
motor disturbances can contribute to an abnormal posture239. 
With the exception of not being able to convert SCS non-responders into 
responders, the human studies were able to essentially replicate the findings in 
the animal studies to some degree. This supports the use of animal studies of this 
kind as a base for exploring underlying mechanisms of SCS effect in humans 
and to find new ways to increase the efficacy and usefulness of this treatment. 
Even though the animal trials have demonstrated successful i.t. 
administration of pharmaceuticals augmenting the effect of SCS it is not 
necessary to exclusively use i.t. administration in clinical trials of adjuvant 
therapy to SCS. As mentioned in Study I a few patients tested oral baclofen 
instead of i.t. administration. The treatment effect was good, but due to side 
effects they all chose to discontinue. In future clinical trials of some of the 
previously mentioned substances oral treatment can still be considered.  
The method of combining SCS and pharmacotherapy could be further 
explored by using other drugs beside baclofen and clonidine. As stated in section 
1.6.2.1 several drugs have already been tested in a laboratory setting. These 
include drugs already in use for peroral medication, such as gabapentin, 
pregabalin, milnacipran and amitryptilin. These drugs are in such frequent use 
among pain patients that it is likely that a substantial number of patients with 
SCS also have tried concomitant medication perorally with one or several of the 
drugs. However, no systematic trials or even retrospective studies have been 
performed.  
Most of the drugs specified in section 1.6.2.1 are not in regular use for 
human i.t. administration. Gabapentin has been used i.t. in a number of animal 
studies, but no publication exists concerning human use. The Polyanalgesic 
Consensus Conference58 has an expert panel on i.t. medication for pain that has 
regularly published recommendations. The latest report, from 2012, not only 
holds a summary of animal trials with i.t. gabapentin, but also informs of an 
ongoing clinical study on human i.t. gabapentin pain treatment58. When more 
experience with i.t. gabapentin is available clinical trials with i.t. gabapentin as 
an adjuvant to SCS may be a possibility. 
Another drug that has been experimentally tested is ketamine343. However, 
this drug is not available for regular oral use, but it has been in use since long i.v. 
for anesthetic purposes and reports on oral administration exist23. The use of 
ketamine is also hampered by its potential for drug abuse and serious side 
effects. Ketamine is not approved for i.t. use, but has been used off-label for that 
purpose since many years, the first report appearing already in 198419. A number 
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of single-patient reports on i.t. ketamine exist, often co-administered with other 
substances – mainly opiates –, and it has successfully been in use long-term for 
i.t. delivery via an implanted pump292,364. There are also, however, reports of 
toxicity154,323,363 and further safety studies are necessary before a potential full 
scale trial with i.t. ketamine as an adjunct to SCS can be carried out. 
Amitryptiline has been tested i.t. in several animal studies since 198324. It 
has several modes of action, including NMDA-receptor antagonism68 (as 
ketamine) and Na+-channel blocking325. The latter characteristic implies actions 
as a local anesthetic. The effect as a spinal anesthetic has been tested in several 
animal studies37,92 as well as effects on pain, both acting alone35 or as an 
adjuvant69,330. Unfortunately reports of serious side effects of i.t. amitryptiline, 
including severe arachnoiditis, in different laboratory animal species have 
appeared89,326. This precludes human testing of i.t. amitryptiline until the risks 
have been further elucidated. 
One of the drugs for i.t. use as a pain treatment that has authority approval 
(FDA, Swedish Medical Products Agency, etc.), namely ziconotide, has not 
been tested in conjunction with SCS – neither in a laboratory setting nor in 
human clinical trials. Ziconotide blocks N-type voltage-sensitive calcium 
channels356. It is only used for i.t. administration and it is approved both for 
nociceptive and neuropathic pain. Ziconotide is, however, more difficult both to 
test and to use long-term, since it has slow onset both of actions and side effects 
and a rather narrow therapeutic window356. Side effects include orthostatic 
hypotension, dizziness, ataxia, abnormal gait, memory impairment, confusion 
and hallucinations309,356. A trial period is generally recommended utilizing an i.t. 
catheter in an in-patient setting, but there is no consensus as to the appropriate 
technique58. If animal studies would demonstrate a suitable facilitating effect of 
ziconitide in SCS clinical trials would be feasible, since the drug is approved for 
i.t. administration. Such a study would have to involve an implanted i.t. catheter 
and continuous drug infusion, instead of the i.t. bolus injections used in Study I 
and III, due to the different time-scale of ziconitide effects and side effects as 
compared to that of baclofen and clonidine. 
The most commonly used type of medication for i.t. pain treatment is 
opioids309. In at least one published study, i.t. opioids have been administered 
concomitantly to SCS via implanted pumps339. In that study the purpose of the 
i.t. administration was not to enhance the effect of SCS, but to treat separate 
symptoms, i.e. midline low-back pain, not improved by SCS. Even though there 
is presently no evidence that opioid mechanisms are involved in the mode of 
action of SCS87, systematic studies of a possible enhancing effect of opioids, as 
well as of a potential counteracting effect of opioid receptor antagonists, are 
warranted. 
Despite the limitations of Studies I-III they provide support to the notion 
that neuropathic pain patients with insufficient pain reduction from SCS should 
be considered for trials with adjuvant pharmacological treatment. A prerequisite 
of course is that the SCS system in itself functions properly, yielding 
comfortable paresthesias covering the painful area. As oral alternatives 
frequently already have been tried in this setting it seems reasonable to 
commence such a trial with i.t. baclofen, because this drug is already approved 
 40 
for i.t. administration. If this fails clonidine should instead be tested. In the 
future it is likely that other i.t. drugs will also prove useful (see Figure 14). 
Studies I-III have been cited in 30 publications: 
Study I42,58,82,105,122,172,192,195,218,243,244,294,295,297,309,310,312,314,315,329,339,368 
Study II105,142,278,294,295,306,308,309,313-315,329,339,350,368 
Study III36,73,105,142,191,312 
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5.1.2 Technical improvement  
Implantation of plate electrodes in an appropriate position is a challenge 
since a procedure under local anesthesia may be demanding and painful to the 
patient and surgery in general anesthesia precludes the use of intra-operative 
testing.  
The finding that intra-operative test stimulation could be performed during 
spinal anesthesia is not only interesting from a technical point of view but also 
concerning the information it conveys on the mechanisms of spinal anesthesia. 
These findings demonstrate that anesthetic agents for spinal anesthesia act more 
on spinal rootlets than on spinal cord afferent pathways. Study IV shows that 
plate electrodes (paddle leads) can be implanted in the low thoracic and lumbar 
region with ease both for implanter and patient using spinal anesthesia. 
Following this publication several other groups have adopted this technique, and 
together with a group in Regina, Saskatchewan, Canada, we have recently 
presented a total of 53 patients undergoing successful plate electrode 
implantation in spinal anesthesia179. Subsequently other implanters have also 
presented their experiences with paddle lead implants in spinal anesthesia, 
combining it with minimally invasive laminotomy techniques291,352. The 
technique cannot, however, be used for implants above the mid-thoracic level, as 
higher spinal anesthesia evidently may affect respiratory function.  
The possibility of using epidural anesthesia instead has been explored for 
paddle lead implants in the low thoracic region91,369. In these studies epidural 
anesthesia was obtained with a catheter inserted into the appropriate level. One 
or several injections of a local anesthetic were performed. Once sufficient 
regional anesthesia was achieved the catheter was removed prior to the surgical 
procedure. An expected advantage compared to spinal anesthesia was the 
possibility to easily iterate injections of the anesthetic if the effect was 
insufficient, avoidance of meningeal puncture and possibly improved 
hemodynamic stability91. A disadvantage, however, could be that if epidural 
adhesions exist they might limit the spread of the anesthetic agent resulting in 
insufficient anesthetic effect. The presence of epidural adhesions is not 
uncommon in patients eligible for paddle lead insertion and in one of the cited 
studies induction of epidural anesthesia actually failed in 7 out of 31 patients, 
necessitating general anesthesia91. In this respect spinal anesthesia has the 
advantage that intrathecal adhesions rarely restrain the spread of the anesthetic. 
The earliest attempt to use epidural anesthesia for SCS implant actually dates 
from 1996, when it was used to facilitate insertion of a cable-type electrode in a 
case were passage of the electrode itself in the epidural space was felt painful by 
the patient280. The first report of a series of patients subject to paddle lead 
implantation in epidural anesthesia is that by  Meyerson et al. in 1998229.  
A different strategy to diminish the pain associated with plate electrode 
insertion in local anesthesia is to minimize the procedure. Beems and van 
Dongen have presented a technique were a series of dilators are used to spread 
paraspinal muscle fibers and enable key-hole entrance to the epidural space for 
paddle lead implant15.  
Another development has been the introduction of a hybrid percutaneous 
and paddle-lead. This is a lead with insulation on the side not facing the dura. It 
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is thicker and wider than a regular cable-type lead but more slender than plate 
electrodes and it can be introduced percutaneously using a specially designed 
needle and a Seldinger-type technique is used for widening of the introductory 
path. Some experience has accumulated in recent years of this technique, 
indicating that the technique works well, with the longest median follow-up of 
one year56,57,165,203,204,359. 
Yet another strategy when implanting paddle leads is to increase the 
likelihood of a proper placement of the electrode by using intra-operative 
neurophysiology, as described in some recent publications10,75,210,304. Without 
any other information in a fully anesthetized patient the laterality of a lead can 
only be decided from intra-operative fluoroscopy. The radiological midline may, 
however, differ from the physiological. By using either EMG75,210,304 or SSEP10 
further information on the laterality can be obtained. With a physiological 
midline placement of the electrode an equal size of the EMG response is to be 
expected from both sides. If a lateral electrode position is needed a larger 
response is aimed for on the side where the electrode should be. SSEP is 
expected to diminish on the intended side, when SCS is turned on, due to 
impulse collision10. These techniques are described in detail in the publications, 
but it is worth noting that at present these techniques only help in determining 
the laterality of an electrode and not the proper positioning in the caudal-
cephalad dimension. 
Modern electrode design can also be of importance. Study IV took place at a 
time when SCS electrodes had four contact areas at most. Modern electrodes 
have up to 16 electrode contacts, which should increase the likelihood that 
simple reprogramming of electrical contacts can solve the problems of 
inadequate paresthesia coverage. No scientific publications substantiating this 
hypothesis exist as yet and the modern multipolar electrodes have not been 
implanted for a sufficient number of years for reliable experience to accumulate. 
In a recent retrospective investigation there was a slight trend that in patients 
with 16 contact electrodes loss of paresthesia coverage could more easily be 
recaptured than in patients with 4 contact electrodes, but the difference was not 
statistically significant164.  
In conclusion the usefulness of spinal anesthesia with intraoperative 
paresthesia testing for implantation of plate electrodes is now well established 
and several other groups have adopted the practice. Although implantation 
techniques have evolved, it is likely that spinal anesthesia will continue to be 
useful in this context. A further development is the use of epidural anesthesia for 
electrode implantation at higher levels than mid-thoracic because the risk of 
respiratory depression should be less. The usefulness of a catheter, as applied in 
the publications concerning paddle lead implant in epidural anesthesia91,369, 
could easily be transferred to the setting of spinal anesthesia, facilitating repeat 
injections if the anesthetic effect diminishes. Repeat spinal injections can, 
however, be performed without an i.t. catheter. 
Study IV has been cited in 17 publications: 
10,14,15,75,82,91,119,177,178,180,190,208,210,219,291,352,369. 
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5.1.3 New indication – IBS –  
IBS is a very common disorder206 with insufficient therapeutic options83 and 
much need for new treatments. As stated in sections 1.3.1.5 and 1.6.2.3, SCS 
effects on gut function have been demonstrated repeatedly and it is logical that 
SCS has been considered for IBS treatment as well. A few beneficial case 
reports on the use of SCS for IBS have been presented173,253,272 - and one report 
demonstrating no effect209 - but Study V, though comprising a small number of 
patients, is the first randomized prospective study.  
There are many possible routes by which SCS could influence 
gastrointestinal disorders such as IBS. The nervous system regulation of the 
gastrointestinal tract is intricate. There is both an intrinsic and an extrinsic neural 
control of the gut7. The intrinsic enteric nervous system is highly complex and 
controls basic gastrointestinal functions. Extrinsic nervous control consists of 
parasympathetic innervation via the vagus nerve and the sacral nerves and 
sympathetic innervations via the splanchnic nerves. Both sympathetic and 
parasympathetic nerves contain afferent and efferent fibres. Afferent 
sympathetic information is carried in the spinal cord through many pathways, 
including not only the spinothalamic tract, but also the dorsal columns as well as 
the spinoreticular, spinomesencephalic and spinosolitary tracts7. Complex brain 
circuitry modulates the gut innervations, together constituting the “brain-gut 
axis”7. Evidence has accumulated that visceral pain is transmitted both in the 
spinothalamic tracts - that normally convey pain impulses - and in postsynaptic 
neurons in the dorsal columns174,242. The dorsal columns have been implicated in 
the transmission of visceral pain in a series of studies based on the prominent 
relieving effect on pain from pelvic cancer by limited midline punctuate 
myelotomies357.  The postsynaptic dorsal column neuron pathway may also have 
an important role in conveying pain from inflammatory visceral processes and in 
a rat study lesions of the pathway did not diminish the reaction to colorectal 
distension under normal circumstances, but under inflammatory conditions such 
a lesion would return the response to normal254. Krames and Foreman have 
hypothesized that SCS exerts its influence on gastrointestinal pain by modifying 
these pathways174. As reported in section 1.6.2.4 animal studies have shown that 
spinal cord neurons firing in response to colonic distension show a reduced 
response after SCS. Another type of mechanism that also may be involved is 
antidromic activation and peripheral release of active substances. This has been 
shown to take place in the use of SCS for peripheral ischemia, where antidromic 
release of CGRP has been implicated in the beneficial effect333. 
Study V indicates that SCS appears to exert beneficial effects in the majority 
of patients with IBS, with a responder rate in the vicinity of that for patients with 
neuropathic pain. There are, however, several limitations of the study, the most 
important being the small size. Larger studies must be performed to verify the 
results, preferably as a multi-center effort. The results of Study V may help in 
performing an adequate power calculation. Another limitation is the lack of 
patient-blinding, since SCS-induced paresthesias were perceived by the patients. 
Also, the method of assessing quality of life, using an NRS, may have been 
insensitive and a more appropriate validated contemporary scale should be 
utilized in future studies. 
 44 
In our study, one patient chose a low intensity stimulation and reported a 
good treatment effect also with stimulation subthreshold to paresthesias. He was, 
however, urged to continue with paresthetic stimulation, as demanded by the 
study protocol. Furthermore, in a personal communication Dr E. Krames has 
reported that the stimulation for his pioneer case eventually was subliminal, but 
with remaining treatment effect. Suddenly the symptoms of IBS, however, 
reappeared and the patient contacted the clinic. On examination the stimulator 
was found to have been turned off (possibly due to exposure to an external 
magnetic field) and when again turned on the beneficial effects returned. As 
described in section 1.3 there have been a few studies presented where SCS at an 
intensity below that needed to produce paresthesias has been used17,66,185,193,194. 
Thus, it is foreseeable that in future studies of SCS for the treatment of IBS 
subliminal treatment could be included. 
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6 CONCLUSIONS 
Insufficient effects by SCS in neuropathic pain, where appropriate coverage 
of the painful region with paresthesias indicate a proper lead position, may be 
improved with the addition of i.t. medication. 
A neuropathic pain patient with insufficient pain relieving effect of SCS, or 
with a diminished previously satisfactory effect, could be subjected to a trial 
with i.t administration of baclofen and/or clonidine; at present, there is more 
evidence for the clinical usefulness of the former drug. 
The effect of combined therapy is likely to last for many years (as 
demonstrated for baclofen), even though a gradual increase of the dosage 
required to maintain a beneficial effect can be anticipated.  
A patient who does not have any appreciable relief of neuropathic pain by 
SCS alone cannot be expected to benefit from adjunctive i.t. pharmacotherapy. 
Plate electrodes can reliably – and comfortably – be implanted under spinal 
anesthesia, which permits intraoperative testing of paresthesia distribution. 
SCS may be a treatment option for IBS when conventional therapy has 
proven ineffective. Further studies with larger patient groups are needed to 
confirm the observations of the present small pilot study. 
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